Author: "Nordlander, Anna" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Nordlander, Anna"' showing total 161 results

Start Over Author "Nordlander, Anna"

161 results on '"Nordlander, Anna"'

1. Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Author: Lahmer, Tobias, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Nucci, Marcio, Besson, Caroline, Itri, Federico, Jaksic, Ozren, Čolović, Natasha, Weinbergerová, Barbora, Seval, Guldane Cengiz, Adžić-Vukičević, Tatjana, Szotkowski, Tomáš, Sili, Uluhan, Dargenio, Michelina, van Praet, Jens, van Doesum, Jaap, Schönlein, Martin, Ráčil, Zdeněk, Žák, Pavel, Poulsen, Christian Bjørn, Magliano, Gabriele, Jiménez, Moraima, Bonuomo, Valentina, Piukovics, Klára, Dragonetti, Giulia, Demirkan, Fatih, Blennow, Ola, Valković, Toni, Gomes Da Silva, Maria, Maertens, Johan, Glenthøj, Andreas, Fernández, Noemí, Bergantim, Rui, Verga, Luisa, Petzer, Verena, Omrani, Ali S., Méndez, Gustavo-Adolfo, Machado, Marina, Ledoux, Marie-Pierre, Bailén, Rebeca, Duarte, Rafael F., Del Principe, Maria Ilaria, Farina, Francesca, Martín-Pérez, Sonia, Dávila-Valls, Julio, Marchetti, Monia, Bilgin, Yavuz M., Fracchiolla, Nicola S., Cattaneo, Chiara, Espigado, Ildefonso, Cordoba, Raul, Collins, Graham P., Labrador, Jorge, Falces-Romero, Iker, Prezioso, Lucia, Meers, Stef, Passamonti, Francesco, Buquicchio, Caterina, López-García, Alberto, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Cuccaro, Annarosa, Garcia-Vidal, Carolina, Busca, Alessandro, Navrátil, Milan, de Jonge, Nick, Biernat, Monika M., Guidetti, Anna, Abu-Zeinah, Ghaith, Samarkos, Michail, Anastasopoulou, Amalia, de Ramón, Cristina, González-López, Tomás José, Hoenigl, Martin, Finizio, Olimpia, Pinczés, László Imre, Ali, Natasha, Vena, Antonio, Tascini, Carlo, Stojanoski, Zlate, Merelli, Maria, Emarah, Ziad, Kohn, Milena, Barać, Aleksandra, Mladenović, Miloš, Mišković, Bojana, Ilhan, Osman, Çolak, Gökçe Melis, Čerňan, Martin, Gräfe, Stefanie K., Ammatuna, Emanuele, Hanakova, Michaela, Víšek, Benjamín, Cabirta, Alba, Nordlander, Anna, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Zambrotta, Giovanni Paolo Maria, Wolf, Dominik, Núñez-Martín-Buitrago, Lucía, Arellano, Elena, Aiello, Tommaso Francesco, García-Sanz, Ramón, Prattes, Juergen, Egger, Matthias, Limongelli, Alessandro, Bavastro, Martina, Cvetanoski, Milche, Dibos, Miriam, Rasch, Sebastian, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio
Published: 2024
Full Text: View/download PDF

2. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Author: Lahmer, Tobias, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Nucci, Marcio, Besson, Caroline, Itri, Federico, Jaksic, Ozren, Čolović, Natasha, Weinbergerová, Barbora, Seval, Guldane Cengiz, Adžić-Vukičević, Tatjana, Szotkowski, Tomáš, Sili, Uluhan, Dargenio, Michelina, van Praet, Jens, van Doesum, Jaap, Schönlein, Martin, Ráčil, Zdeněk, Žák, Pavel, Poulsen, Christian Bjørn, Magliano, Gabriele, Jiménez, Moraima, Bonuomo, Valentina, Piukovics, Klára, Dragonetti, Giulia, Demirkan, Fatih, Blennow, Ola, Valković, Toni, Gomes Da Silva, Maria, Maertens, Johan, Glenthøj, Andreas, Fernández, Noemí, Bergantim, Rui, Verga, Luisa, Petzer, Verena, Omrani, Ali S., Méndez, Gustavo-Adolfo, Machado, Marina, Ledoux, Marie-Pierre, Bailén, Rebeca, Duarte, Rafael F., Del Principe, Maria Ilaria, Farina, Francesca, Martín-Pérez, Sonia, Dávila-Valls, Julio, Marchetti, Monia, Bilgin, Yavuz M., Fracchiolla, Nicola S., Cattaneo, Chiara, Espigado, Ildefonso, Cordoba, Raul, Collins, Graham P., Labrador, Jorge, Falces-Romero, Iker, Prezioso, Lucia, Meers, Stef, Passamonti, Francesco, Buquicchio, Caterina, López-García, Alberto, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Cuccaro, Annarosa, Garcia-Vidal, Carolina, Busca, Alessandro, Navrátil, Milan, de Jonge, Nick, Biernat, Monika M., Guidetti, Anna, Abu-Zeinah, Ghaith, Samarkos, Michail, Anastasopoulou, Amalia, de Ramón, Cristina, González-López, Tomás José, Hoenigl, Martin, Finizio, Olimpia, Pinczés, László Imre, Ali, Natasha, Vena, Antonio, Tascini, Carlo, Stojanoski, Zlate, Merelli, Maria, Emarah, Ziad, Kohn, Milena, Barać, Aleksandra, Mladenović, Miloš, Mišković, Bojana, Ilhan, Osman, Çolak, Gökçe Melis, Čerňan, Martin, Gräfe, Stefanie K., Ammatuna, Emanuele, Hanakova, Michaela, Víšek, Benjamín, Cabirta, Alba, Nordlander, Anna, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Zambrotta, Giovanni Paolo Maria, Wolf, Dominik, Núñez-Martín-Buitrago, Lucía, Arellano, Elena, Aiello, Tommaso Francesco, García-Sanz, Ramón, Prattes, Juergen, Egger, Matthias, Limongelli, Alessandro, Bavastro, Martina, Cvetanoski, Milche, Dibos, Miriam, Rasch, Sebastian, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio
Published: 2024
Full Text: View/download PDF

3. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey

Author: Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Blennow, Ola, da Silva, Maria Gomes, Glenthøj, Andreas, van Doesum, Jaap, Bilgin, Yavuz M, López-García, Alberto, Itri, Federico, Rodrigues, Raquel Nunes, Weinbergerová, Barbora, Farina, Francesca, Dragonetti, Giulia, Venemyr, Caroline Berg, van Praet, Jens, Jaksic, Ozren, Valković, Toni, Falces-Romero, Iker, Martín-Pérez, Sonia, Jiménez, Moraima, Dávila-Valls, Julio, Schönlein, Martin, Ammatuna, Emanuele, Meers, Stef, Delia, Mario, Stojanoski, Zlate, Nordlander, Anna, Lahmer, Tobias, Pinczés, László Imre, Buquicchio, Caterina, Piukovics, Klára, Ormazabal-Vélez, Irati, Fracchiolla, Nicola, Samarkos, Michail, Méndez, Gustavo-Adolfo, Hernández-Rivas, José-Ángel, Espigado, Ildefonso, Cernan, Martin, Petzer, Verena, Lamure, Sylvain, di Blasi, Roberta, de Almedia, Joyce Marques, Dargenio, Michelina, Biernat, Monika M, Sciumè, Mariarita, de Ramón, Cristina, de Jonge, Nick, Batinić, Josip, Aujayeb, Avinash, Marchetti, Monia, Fouquet, Guillemette, Fernández, Noemí, Zambrotta, Giovanni, Sacchi, Maria Vittoria, Guidetti, Anna, Demirkan, Fatih, Prezioso, Lucia, Ráčil, Zdeněk, Nucci, Marcio, Mladenović, Miloš, Liévin, Raphaël, Hanáková, Michaela, Gräfe, Stefanie, Sili, Uluhan, Machado, Marina, Cattaneo, Chiara, Adžić-Vukičević, Tatjana, Verga, Luisa, Labrador, Jorge, Rahimli, Laman, Bonanni, Matteo, Passamonti, Francesco, Pagliuca, Antonio, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Busca, Alessandro, Cornely, Oliver A, Serrano, Laura, Susana, José-María Ribera-Santa, Meletiadis, Joseph, Tsirigotis, Panagiotis, Coppola, Nicola, Mikulska, Malgorzata, Erben, Nurettin, Besson, Caroline, Merelli, Maria, González-López, Tomás-José, Loureiro-Amigo, Jorge, García-Vidal, Carolina, de Kort, Elizabeth, Cuccaro, Annarosa, Zompi, Sofia, Reizine, Florian, Finizio, Olimpia, Duléry, Rémy, Calbacho, Maria, Abu-Zeinah, Ghaith, and Malak, Sandra
Subjects: Biotechnology, Emerging Infectious Diseases, Biodefense, Immunization, Infectious Diseases, Lung, Vaccine Related, Cancer, Prevention, Good Health and Well Being, Adult, Humans, COVID-19, SARS-CoV-2, COVID-19 Testing, Hematologic Neoplasms, Antibodies, Monoclonal, Antiviral Agents, Antibodies, Viral, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology
Abstract: Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received ≤2 vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P < .001), active HM (P < .001), and severe and critical COVID-19 (P = .007 and P < .001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P < .001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P < .001) or combined with antivirals (P = .009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.
Published: 2022

4. Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG

Author: Giacobbe, Daniele Roberto, Dettori, Silvia, Di Pilato, Vincenzo, Asperges, Erika, Ball, Lorenzo, Berti, Enora, Blennow, Ola, Bruzzone, Bianca, Calvet, Laure, Capra Marzani, Federico, Casabella, Antonio, Choudaly, Sofia, Dartevel, Anais, De Pascale, Gennaro, Di Meco, Gabriele, Fallon, Melissa, Galerneau, Louis-Marie, Gallego, Miguel, Giacomini, Mauro, González Sáez, Adolfo, Hänsel, Luise, Icardi, Giancarlo, Koehler, Philipp, Lagrou, Katrien, Lahmer, Tobias, Lewis White, P., Magnasco, Laura, Marchese, Anna, Marelli, Cristina, Marín-Arriaza, Mercedes, Martin-Loeches, Ignacio, Mekontso-Dessap, Armand, Mikulska, Malgorzata, Mularoni, Alessandra, Nordlander, Anna, Poissy, Julien, Russelli, Giovanna, Signori, Alessio, Tascini, Carlo, Vaconsin, Louis-Maxime, Vargas, Joel, Vena, Antonio, Wauters, Joost, Pelosi, Paolo, Timsit, Jean-Francois, and Bassetti, Matteo
Published: 2023
Full Text: View/download PDF

5. COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP

Author: Busca, Alessandro, Salmanton-García, Jon, Corradini, Paolo, Marchesi, Francesco, Cabirta, Alba, Di Blasi, Roberta, Dulery, Remy, Lamure, Sylvain, Farina, Francesca, Weinbergerová, Barbora, Batinić, Josip, Nordlander, Anna, López-García, Alberto, Drgoňa, Ľuboš, Espigado-Tocino, Ildefonso, Falces-Romero, Iker, García-Sanz, Ramón, García-Vidal, Carolina, Guidetti, Anna, Khanna, Nina, Kulasekararaj, Austin, Maertens, Johan, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A, and Pagano, Livio
Subjects: Prevention, Infection, Good Health and Well Being, COVID-19, Humans, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes
Abstract: The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
Published: 2022

6. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

Author: Martín-Vallejo, Francisco Javier, Zdziarski, Przemyslaw, Zarrinfer, Hossein, Wittig, Jana, Win, Sein, Wai-Man, Vivien, Víšek, Benjamín, Vinh, Donald C., Vehreschild, Maria, Varricchio, Gina, Tsirigotis, Panagiotis, Torres-Tienza, Ana, Tanase, Alina Daniela, Tafuri, Agostino, Stamouli, Maria, Sramek, Jiří, Soussain, Carole, Shirinova, Ayten, Schubert, Jörg, Schalk, Enrico, Salehi, Mohammad Reza, Saleh, Modar, Rosati, Giorgio, Roldán, Elisa, Reizine, Florian, Rêgo, Mayara, Regalado-Artamendi, Isabel, Popova, Marina, Pinto, Fernando, Philippe, Laure, Orth, Hans Martin, Ommen, Hans-Beier, Obr, Aleš, Núñez-Martín-Buitrago, Lucía, Noël, Nicolas, Neuhann, Julia, Nadali, Gianpaolo, Nacov, Julia A., Munhoz Alburquerque, Ana M., Mitra, Maria Enza, Mikulska, Malgorzata, Mellinghoff, Sibylle, Mechtel, Ben, Martín-González, Juan-Alberto, Malak, Sandra, Loureiro-Amigo, Jorge, Lorenzo De La Peña, Lisset, Liberti, Giulia, Landau, Marianne, Lacej, Ira, Kolditz, Martin, Kho, Chi Shan, Khedr, Reham Abdelaziz, Karthaus, Meinolf, Karlsson, Linda Katharina, Jiménez-Lorenzo, María-Josefa, Izuzquiza, Macarena, Hoell-Neugebauer, Baerbel, Herbrecht, Raoul, Heath, Christopher H., Guolo, Fabio, Grothe, Jan, Giordano, Antonio, Gerasymchuk, Sergey, García-Sanz, Ramón, García-Poutón, Nicole, Funke, Vaneuza Araújo Moreira, Fung, Monica, Flasshove, Charlotte, Fianchi, Luana, Essame, Jenna, Egger, Matthias, Drenou, Bernard, Dragonetti, Giulia, Desole, Maximilian, Della Pepa, Roberta, Deau Fischer, Bénédicte, De Kort, Elizabeth, De Cabo, Erik, Danion, François, Daguindau, Etienne, Cushion, Tania, Cremer, Louise, Criscuolo, Marianna, Cordini, Gregorio, Cingolani, Antonella, Ciceri, Fabio, Chowdhury, Fazle Rabbi, Chelysheva, Ekaterina, Chauchet, Adrien, Chai, Louis Yi Ann, Ceesay, M. Mansour, Busch, Elena, Brehon, Mathias, Borducchi, Davimar M.M., Booth, Stephen, Bologna, Serge, Berg Venemyr, Caroline, Bailén-Almorox, Rebeca, Antoniadou, Anastasia, Anastasopoulou, Amalia N., Altuntaş, Fevzi, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Weinbergerová, Barbora, Itri, Federico, Dávila-Valls, Julio, Martín-Pérez, Sonia, Glenthøj, Andreas, Hersby, Ditte Stampe, Gomes Da Silva, Maria, Nunes Rodrigues, Raquel, López-García, Alberto, Córdoba, Raúl, Bilgin, Yavuz M., Falces-Romero, Iker, El-Ashwah, Shaimaa, Emarah, Ziad, Besson, Caroline, Kohn, Milena, Van Doesum, Jaap, Ammatuna, Emanuele, Marchetti, Monia, Labrador, Jorge, Zambrotta, Giovanni Paolo Maria, Verga, Luisa, Jaksic, Ozren, Nucci, Marcio, Piukovics, Klára, Cabirta-Touzón, Alba, Jiménez, Moraima, Arellano, Elena, Espigado, Ildefonso, Blennow, Ola, Nordlander, Anna, Meers, Stef, Vian Praet, Jens, Aiello, Tommaso Francesco, Garcia-Vidal, Carolina, Fracchiolla, Nicola S., Sciumè, Mariarita, Seval, Guldane Cengiz, Žák, Pavel, Buquicchio, Caterina, Tascini, Carlo, Gräfe, Stefanie K., Schönlein, Martin, Adžić-VUKIČEVIĆ, Tatjana, Bonuomo, Valentina, Cattaneo, Chiara, Nizamuddin, Summiya, Čerňan, Martin, Plantefeve, Gaëtan, Prin, Romane, Szotkovski, Tomas, Collins, Graham P., Dargenio, Michelina, Petzer, Verena, Wolf, Dominik, Čolović, Natasha, Prezioso, Lucia, Valković, Toni, Passamonti, Francesco, Méndez, Gustavo-Adolfo, Sili, Uluhan, Vena, Antonio, Bavastro, Martina, Limongelli, Alessandro, Duarte, Rafael F., Ledoux, Marie-Pierre, Cvetanoski, Milche, Stojanoski, Zlate, Machado, Marina, Batinić, Josip, Magliano, Gabriele, Biernat, Monika M., Pantić, Nikola, Poulsen, Christian Bjørn, Cuccaro, Annarosa, Del Principe, Maria Ilaria, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Busca, Alessandro, Demirkan, Fatih, Ijaz, Marriyam, Klimko, Nikolai, Stoma, Igor, Khostelidi, Sofya, Fernández, Noemí, Omrani, Ali S., Bergantim, Rui, De Jonge, Nick, Fouquet, Guillemette, Navrátil, Milan, Abu-Zeinah, Ghaith, Samarkos, Michail, Maertens, Johan, De Ramón, Cristina, Guidetti, Anna, Magyari, Ferenc, González-López, Tomás José, Lahmer, Tobias, Finizio, Olimpia, Ali, Natasha, Pinczés, László Imre, Lavilla-Rubira, Esperanza, Romano, Alessandra, Merelli, Maria, Delia, Mario, Calbacho, Maria, Meletiadis, Joseph, Antić, Darko, Hernández-Rivas, José-Ángel, Marques De Almeida, Joyce, Al-Khabori, Murtadha, Hoenigl, Martin, Tisi, Maria Chiara, Khanna, Nina, Barać, Aleksandra, Eisa, Noha, Di Blasi, Roberta, Liévin, Raphaël, Miranda-Castillo, Carolina, Bahr, Nathan C., Lamure, Sylvain, Papa, Mario Virgilio, Yahya, Ayel, Aujayeb, Avinash, Novák, Jan, Erben, Nurettin, Fernández-Galán, María, Ribera-Santa Susana, José-María, Rinaldi, Ikhwan, Fazzi, Rita, Piedimonte, Monica, Duléry, Rémy, Gonzaga, Yung, Soto-Silva, Andrés, Sapienza, Giuseppe, Serris, Alexandra, Drgoňa, Ľuboš, Groh, Ana, Serrano, Laura, Gavriilaki, Eleni, Tragiannidis, Athanasios, Prattes, Juergen, Coppola, Nicola, Otašević, Vladimir, Mladenović, Miloš, Mitrović, Mirjana, Mišković, Bojana, Jindra, Pavel, Zompi, Sofia, Sacchi, Maria Vittoria, Krekeler, Carolin, Shumilov, Evgenii, Infante, Maria Stefania, García-Bordallo, Daniel, Çolak, Gökçe Melis, Mayer, Jiří, Nygaard, Marietta, Hanáková, Michaela, Ráčil, Zdeněk, Quattrone, Martina, Bonanni, Matteo, Koehler, Philipp, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio
Published: 2024
Full Text: View/download PDF

7. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

Author: MARQUES DE ALMEIDA, Joyce, HERNÁNDEZ-RIVAS, José-Ángel, GUIDETTI, Anna, FINIZIO, Olimpia, STOJANOSKI, Zlate, CVETANOSKI, Milche, MELETIADIS, Joseph, DE JONGE, Nick, ANTIĆ, Darko, ALI, Natasha, TISI, Maria Chiara, SERRANO, Laura, PLANTEFEVE, Gaëtan, KHANNA, Nina, HOENIGL, Martin, ČERŇAN, Martin, MIRANDA-CASTILLO, Carolina, FERNÁNDEZ-GALÁN, María, SERRIS, Alexandra, ERBEN, Nurettin, DULÉRY, Rémy, AUJAYEB, Avinash, PAPA, Mario Virgilio, NOVÁK, Jan, DELIA, Mario, SAPIENZA, Giuseppe, REIZINE, Florian, OMRANI, Ali S., DI BLASI, Roberta, LAMURE, Sylvain, DRGOŇA, Ľuboš, COPPOLA, Nicola, BATINIĆ, Josip, AL-KHABORI, Murtadha, RIBERA-SANTA SUSANA, José-María, PIEDIMONTE, Monica, LOUREIRO-AMIGO, Jorge, FOUQUET, Guillemette, FAZZI, Rita, DANION, François, SCHUBERT, Jörg, HOELL-NEUGEBAUER, Baerbel, BAHR, Nathan C., YAHIA, Ayel Omar, TORRES-ATIENZA, Ana, RINALDI, Ikhwan, POPOVA, Marina, OMMEN, Hans-Beier, MITRA, Maria Enza, MIKULSKA, Malgorzata, LACEJ, Ira, KHOSTELIDI, Sofya, WIN, Sein, VINH, Donald, SALEH, Modar, PRATTES, Juergen, JINDRA, Pavel, GUOLO, Fabio, DELLA PEPA, Roberta, CHELYSHEVA, Ekaterina, ZDZIARSKI, Przemyslaw, WAI-MAN, Vivien, SOTO-SILVA, Andrés, ORTH, Hans Martin, MALAK, Sandra, LORENZO DE LA PEÑA, Lisset, KOLDITZ, Martin, Shan KHO, Chi, HEATH, Christopher H., GROH, Ana, GAVRIILAKI, Eleni, FUNG, Monica, EGGER, Matthias, DE KORT, Elizabeth, DE CABO, Erik, CUSHION, Tania, CHOWDHURY, Fazle Rabbi, CEESAY, M. Mansour, BREHON, Mathias, VARRICCHIO, Gina, TAFURI, Agostino, JIMÉNEZ-LORENZO, María-Josefa, KLIMKO, Nikolai, TSIRIGOTIS, Panagiotis, ANTONIADOU, Anastasia, VEHRESCHILD, Maria, Rossi, Giuseppe, Salmanton-García, Jon, Cattaneo, Chiara, Marchesi, Francesco, Dávila-Valls, Julio, Martín-Pérez, Sonia, Itri, Federico, López-García, Alberto, Glenthøj, Andreas, Gomes da Silva, Maria, Besson, Caroline, Marchetti, Monia, Weinbergerová, Barbora, Jaksic, Ozren, Jiménez, Moraima, Bilgin, Yavuz M., Van Doesum, Jaap, Farina, Francesca, Žák, Pavel, Verga, Luisa, Collins, Graham P., Bonuomo, Valentina, Van Praet, Jens, Nucci, Marcio, Meers, Stef, Espigado, Ildefonso, Fracchiolla, Nicola S., Valković, Toni, Poulsen, Christian Bjørn, Čolović, Natasha, Dragonetti, Giulia, Ledoux, Marie-Pierre, Tascini, Carlo, Buquicchio, Caterina, Blennow, Ola, Passamonti, Francesco, Machado, Marina, Labrador, Jorge, Duarte, Rafael F., Schönlein, Martin, Prezioso, Lucia, Falces-Romero, Iker, Kulasekararaj, Austin, Garcia-Vidal, Carolina, Fernández, Noemí, Abu-Zeinah, Ghaith, Ormazabal-Vélez, Irati, Adžić-Vukičević, Tatjana, Piukovics, Klára, Stoma, Igor, Cuccaro, Annarosa, Magliano, Gabriele, Szotkowski, Tomáš, González-López, Tomás-José, El-Ashwah, Shaimaa, Bergantim, Rui, Sili, Uluhan, Maertens, Johan, Demirkan, Fatih, De Ramón, Cristina, Petzer, Verena, Del Principe, Maria Ilaria, Navrátil, Milan, Dargenio, Michelina, Seval, Guldane Cengiz, Samarkos, Michail, Ráčil, Zdeněk, Pinczés, László Imre, Lahmer, Tobias, Busca, Alessandro, Méndez, Gustavo-Adolfo, Vena, Antonio, Biernat, Monika M., Merelli, Maria, Calbacho, Maria, Barać, Aleksandra, Bavastro, Martina, Limongelli, Alessandro, Ilhan, Osman, Wolf, Dominik, Çolak, Gökçe Melis, García-Sanz, Ramón, Emarah, Ziad, Mišković, Bojana, Gräfe, Stefanie K., Mladenović, Miloš, Aiello, Tommaso Francesco, Núñez-Martín-Buitrago, Lucía, Nordlander, Anna, Arellano, Elena, Zambrotta, Giovanni Paolo Maria, Ammatuna, Emanuele, Cabirta, Alba, Sacchi, Maria Vittoria, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Hanakova, Michaela, Rahimli, Laman, Cordoba, Raul, Cornely, Oliver A., and Pagano, Livio
Published: 2023
Full Text: View/download PDF

8. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

Author: van Doesum, Jaap A., Salmanton-García, Jon, Marchesi, Francesco, Di Blasi, Roberta, Falces-Romero, Iker, Cabirta, Alba, Farina, Francesca, Besson, Caroline, Weinbergerová, Barbora, Van Praet, Jens, Schönlein, Martin, López-García, Alberto, Lamure, Sylvain, Guidetti, Anna, De Ramón-Sánchez, Cristina, Batinić, Josip, Gavriilaki, Eleni, Tragiannidis, Athanasios, Tisi, Maria Chiara, Plantefeve, Gaëtan, Petzer, Verena, Ormazabal-Vélez, Irati, Marques de Almeida, Joyce, Marchetti, Monia, Maertens, Johan, Machado, Marina, Kulasekararaj, Austin, Hernández-Rivas, José-Ángel, Gomes da Silva, Maria, Fernández, Noemí, Espigado, Ildefonso, Drgoňa, Ľuboš, Dragonetti, Giulia, Metafuni, Elisabetta, Calbacho, Maria, Blennow, Ola, Wolf, Dominik, van Anrooij, Bjorn, Nunes Rodrigues, Raquel, Nordlander, Anna, Martín-González, Juan-Alberto, Liévin, Raphaël, Jiménez, Moraima, Gräfe, Stefanie K., García-Sanz, Ramón, Córdoba, Raúl, Rahimli, Laman, van Meerten, Tom, Cornely, Oliver A., and Pagano, Livio
Published: 2023
Full Text: View/download PDF

9. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Author: Piukovics, Klára, De Ramón, Cristina, Danion, François, Yahya, Ayel, Guidetti, Anna, Garcia-Vidal, Carolina, Sili, Uluhan, Meletiadis, Joseph, De Kort, Elizabeth, Verga, Luisa, Serrano, Laura, Erben, Nurettin, Di Blasi, Roberta, Tragiannidis, Athanasios, Ribera-Santa Susana, José-María, Ommen, Hans-Beier, Busca, Alessandro, Coppola, Nicola, Bergantim, Rui, Dragonetti, Giulia, Criscuolo, Marianna, Fianchi, Luana, Bonanni, Matteo, Soto-Silva, Andrés, Mikulska, Malgorzata, Machado, Marina, Shan Kho, Chi, Hassan, Nazia, Gavriilaki, Eleni, Cordini, Gregorio, Chi, Louis Yi Ann, Eggerer, Matthias, Hoenigl, Martin, Prattes, Juergen, Jiménez-Lorenzo, María-Josefa, Zompi, Sofia, Zambrotta, Giovanni Paolo Maria, Çolak, Gökçe Melis, García-Poutón, Nicole, Aiello, Tommaso Francesco, Prin, Romane, Stamouli, Maria, Samarkos, Michail, Salmanton-García, Jon, Marchesi, Francesco, Gomes da Silva, Maria, Farina, Francesca, Dávila-Valls, Julio, Bilgin, Yavuz M., Glenthøj, Andreas, Falces-Romero, Iker, Van Doesum, Jaap, Labrador, Jorge, Buquicchio, Caterina, El-Ashwah, Shaimaa, Petzer, Verena, Van Praet, Jens, Schönlein, Martin, Dargenio, Michelina, Méndez, Gustavo-Adolfo, Meers, Stef, Itri, Federico, Giordano, Antonio, Pinczés, László Imre, Espigado, Ildefonso, Stojanoski, Zlate, López-García, Alberto, Prezioso, Lucia, Jaksic, Ozren, Vena, Antonio, Fracchiolla, Nicola S., González-López, Tomás José, Colović, Natasa, Delia, Mario, Weinbergerová, Barbora, Marchetti, Monia, Marques de Almeida, Joyce, Finizio, Olimpia, Besson, Caroline, Biernat, Monika M., Valković, Toni, Lahmer, Tobias, Cuccaro, Annarosa, Ormazabal-Vélez, Irati, Batinić, Josip, Fernández, Noemí, De Jonge, Nick, Tascini, Carlo, Anastasopoulou, Amalia N., Duléry, Rémy, Del Principe, Maria Ilaria, Plantefeve, Gaëtan, Papa, Mario Virgilio, Nucci, Marcio, Jiménez, Moraima, Aujayeb, Avinash, Hernández-Rivas, José-Ángel, Merelli, Maria, Cattaneo, Chiara, Blennow, Ola, Nordlander, Anna, Cabirta, Alba, Varricchio, Gina, Sacchi, Maria Vittoria, Cordoba, Raul, Arellano, Elena, Gräfe, Stefanie K., Wolf, Dominik, Emarah, Ziad, Ammatuna, Emanuele, Hersby, Ditte Stampe, Martín-Pérez, Sonia, Nunes Rodrigues, Raquel, Rahimli, Laman, Pagano, Livio, and Cornely, Oliver A.
Published: 2023
Full Text: View/download PDF

10. MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY

Author: SALMANTON-GARCÍA, Jon, MARCHESI, Francesco, KOEHLER, Philipp, WEINBERGEROVÁ, Barbora, ČOLOVIĆ, Natasa, FALCES-ROMERO, Iker, BUQUICCHIO, Caterina, FARINA, Francesca, PRAET, Jens VAN, BIERNAT, Monika M., ITRI, Federico, PREZIOSO, Lucia, TASCINI, Carlo, VENA, Antonio, ROMANO, Alessandra, DELIA, Mario, DÁVILA-VALLS, Julio, MARTÍN-PÉREZ, Sonia, LAVILLA-RUBIRA, Esperanza, ADŽIĆ-VUKIČEVIĆ, Tatjana, GARCÍA-BORDALLO, Daniel, LÓPEZ-GARCÍA, Alberto, CRISCUOLO, Mariana, PETZER, Verena, FRACCHIOLLA, Nicola S., ESPIGADO, Ildefonso, SILI, Uluhan, MEERS, Stef, ERBEN, Nurettin, CATTANEO, Chiara, TRAGIANNIDIS, Athanasios, GAVRIILAKI, Eleni, SCHÖNLEIN, Martin, MITROVIC, Mirjana, PANTIC, Nikola, MERELLI, Maria, LABRADOR, Jorge, HERNÁNDEZ-RIVAS, José-Ángel, GLENTHØJ, Andreas, FOUQUET, Guillemette, DEL PRINCIPE, Maria Ilaria, DARGENIO, Michelina, CALBACHO, María, BESSON, Caroline, KOHN, Milena, GRÄFE, Stefanie, HERSBY, Ditte Stampe, ARELLANO, Elena, MelisÇOLAK, Gökçe, WOLF, Dominik, MARCHETTI, Monia, NORDLANDER, Anna, BLENNOW, Ola, CORDOBA, Raul, MIŠKOVIĆ, Bojana, MLADENOVIĆ, Miloš, BAVASTRO, Martina, LIMONGELLI, Alessandro, RAHIMLI, Laman, PAGANO, Livio, and CORNELY, Oliver A.
Published: 2023
Full Text: View/download PDF

11. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Author: Serrano, Laura, Ribera-Santa Susana, José-María, Meletiadis, Joseph, Tsirigotis, Panagiotis, Coppola, Nicola, Mikulska, Malgorzata, Erben, Nurettin, Besson, Caroline, Merelli, Maria, González-López, Tomás-José, Loureiro-Amigo, Jorge, García-Vidal, Carolina, Kort, Elizabeth de, Cuccaro, Annarosa, Zompi, Sofia, Reizine, Florian, Finizio, Olimpia, Duléry, Rémy, Calbacho, Maria, Abu-Zeinah, Ghaith, Malak, Sandra, Zdziarski, Przemyslaw, Varrichio, Gina, Tragiannidis, Athanasios, Plantefeve, Gaëtan, Duarte, Rafael, Danion, François, Tisi, Maria Chiara, Sakellari, Ioanna, Karthaus, Meinholf, Groh, Ana, Fung, Monica, Emarah, Ziad, Coronel-Ayala, Omar-Francisco, Ann Chai, Louis Yi, Brehon, Mathias, Bonuomo, Valentina, Wolf, Dominik, Wittig, Jana, Vehreschild, Maria, Papa, Mario Virgilio, Neuhann, Julia, Jiménez-Lorenzo, María-Josefa, Grothe, Jan, Gavriilaki, Eleni, García-Sanz, Ramón, García-Poutón, Nicole, El-Ashwah, Shaimaa Saber, Eggerer, Matthias, Cordoba, Raul, Çolak, Gökçe Melis, Arellano, Elena, Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Blennow, Ola, Gomes da Silva, Maria, Glenthøj, Andreas, van Doesum, Jaap, Bilgin, Yavuz M., López-García, Alberto, Itri, Federico, Nunes Rodrigues, Raquel, Weinbergerová, Barbora, Farina, Francesca, Dragonetti, Giulia, Berg Venemyr, Caroline, van Praet, Jens, Jaksic, Ozren, Valković, Toni, Falces-Romero, Iker, Martín-Pérez, Sonia, Jiménez, Moraima, Dávila-Valls, Julio, Schönlein, Martin, Ammatuna, Emanuele, Meers, Stef, Delia, Mario, Stojanoski, Zlate, Nordlander, Anna, Lahmer, Tobias, Imre Pinczés, László, Buquicchio, Caterina, Piukovics, Klára, Ormazabal-Vélez, Irati, Fracchiolla, Nicola, Samarkos, Michail, Méndez, Gustavo-Adolfo, Hernández-Rivas, José-Ángel, Espigado, Ildefonso, Cernan, Martin, Petzer, Verena, Lamure, Sylvain, di Blasi, Roberta, Marques de Almedia, Joyce, Dargenio, Michelina, Biernat, Monika M., Sciumè, Mariarita, de Ramón, Cristina, de Jonge, Nick, Batinić, Josip, Aujayeb, Avinash, Marchetti, Monia, Fouquet, Guillemette, Fernández, Noemí, Zambrotta, Giovanni, Sacchi, Maria Vittoria, Guidetti, Anna, Demirkan, Fatih, Prezioso, Lucia, Ráčil, Zdeněk, Nucci, Marcio, Mladenović, Miloš, Liévin, Raphaël, Hanáková, Michaela, Gräfe, Stefanie, Sili, Uluhan, Machado, Marina, Cattaneo, Chiara, Adžić-Vukičević, Tatjana, Verga, Luisa, Labrador, Jorge, Rahimli, Laman, Bonanni, Matteo, Passamonti, Francesco, Pagliuca, Antonio, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Busca, Alessandro, and Cornely, Oliver A.
Published: 2022
Full Text: View/download PDF

12. The Impact of Pretransplant Respiratory Virus Detection on Posttransplant Outcomes in Children Undergoing Hematopoietic Cell Transplantation.

Author: Kim, Sara Ruth, Nordlander, Anna, Xie, Hu, Kim, Yae-Jean, Ogimi, Chikara, Thakar, Monica S, Leisenring, Wendy, Englund, Janet A, Boeckh, Michael, and Waghmare, Alpana
Subjects: *CORD blood transplantation, *HEMATOPOIETIC stem cell transplantation, *BLOOD irradiation, *RESPIRATORY infections, *TRANSPLANTATION of organs, tissues, etc., *MICROBIAL sensitivity tests, *VIRAL load, *PATIENTS, *RESPIRATORY syncytial virus, *LYMPHOCYTE count, *RETROSPECTIVE studies, *REVERSE transcriptase polymerase chain reaction, *AGE distribution, *DESCRIPTIVE statistics, *RESPIRATORY syncytial virus infections, *SURGICAL complications, *LONGITUDINAL method, *MEDICAL records, *ACQUISITION of data, *COMORBIDITY, *CHILDREN
Abstract: Background Pretransplant respiratory virus (RV) infections have been associated with negative transplant outcomes in adult hematopoietic cell transplantation (HCT) recipients. In the era of HCT delay because of high-risk RVs, we examined the impact of pretransplant RV detection on transplant outcomes in pediatric HCT recipients. Methods This retrospective cohort study included pediatric myeloablative allogeneic HCT recipients from 2010 to 2019. All patients were screened for RV at least once within 90 days before HCT using reverse transcriptase polymerase chain reaction (PCR), regardless of symptoms. Posttransplant outcomes included days alive and out of hospital and progression to lower respiratory tract infection (LRTI). Results Among 310 patients, 134 had an RV detected in the 90 days before HCT. In univariable analysis, transplant factors including younger age, total body irradiation, umbilical cord blood transplantation, lymphocyte count <100/mm3, HCT comorbidity index score ≥3, and viral factors including symptomatic infection, human rhinovirus as a virus type, and symptomatic pretransplant upper respiratory tract infection were associated with fewer days alive and out of hospital. In multivariable analysis, transplant factors remained significant, but not viral factors. There was a higher incidence of progression to posttransplant LRTI with the same pretransplant RV if the last positive PCR before HCT was ≤30 days compared with >30 days (P =.007). Conclusions In the setting of recommending HCT delay for high-risk RVs, symptomatic upper respiratory tract infection, including human rhinovirus infections, may lead to increased duration of hospitalization and early progression to LRTI when transplantation is performed within 30 days of the last positive PCR test. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

13. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

Author: Salmanton-García, Jon, primary, Marchesi, Francesco, additional, Farina, Francesca, additional, Weinbergerová, Barbora, additional, Itri, Federico, additional, Dávila-Valls, Julio, additional, Martín-Pérez, Sonia, additional, Glenthøj, Andreas, additional, Hersby, Ditte Stampe, additional, Gomes Da Silva, Maria, additional, Nunes Rodrigues, Raquel, additional, López-García, Alberto, additional, Córdoba, Raúl, additional, Bilgin, Yavuz M., additional, Falces-Romero, Iker, additional, El-Ashwah, Shaimaa, additional, Emarah, Ziad, additional, Besson, Caroline, additional, Kohn, Milena, additional, Van Doesum, Jaap, additional, Ammatuna, Emanuele, additional, Marchetti, Monia, additional, Labrador, Jorge, additional, Zambrotta, Giovanni Paolo Maria, additional, Verga, Luisa, additional, Jaksic, Ozren, additional, Nucci, Marcio, additional, Piukovics, Klára, additional, Cabirta-Touzón, Alba, additional, Jiménez, Moraima, additional, Arellano, Elena, additional, Espigado, Ildefonso, additional, Blennow, Ola, additional, Nordlander, Anna, additional, Meers, Stef, additional, Vian Praet, Jens, additional, Aiello, Tommaso Francesco, additional, Garcia-Vidal, Carolina, additional, Fracchiolla, Nicola S., additional, Sciumè, Mariarita, additional, Seval, Guldane Cengiz, additional, Žák, Pavel, additional, Buquicchio, Caterina, additional, Tascini, Carlo, additional, Gräfe, Stefanie K., additional, Schönlein, Martin, additional, Adžić-VUKIČEVIĆ, Tatjana, additional, Bonuomo, Valentina, additional, Cattaneo, Chiara, additional, Nizamuddin, Summiya, additional, Čerňan, Martin, additional, Plantefeve, Gaëtan, additional, Prin, Romane, additional, Szotkovski, Tomas, additional, Collins, Graham P., additional, Dargenio, Michelina, additional, Petzer, Verena, additional, Wolf, Dominik, additional, Čolović, Natasha, additional, Prezioso, Lucia, additional, Valković, Toni, additional, Passamonti, Francesco, additional, Méndez, Gustavo-Adolfo, additional, Sili, Uluhan, additional, Vena, Antonio, additional, Bavastro, Martina, additional, Limongelli, Alessandro, additional, Duarte, Rafael F., additional, Ledoux, Marie-Pierre, additional, Cvetanoski, Milche, additional, Stojanoski, Zlate, additional, Machado, Marina, additional, Batinić, Josip, additional, Magliano, Gabriele, additional, Biernat, Monika M., additional, Pantić, Nikola, additional, Poulsen, Christian Bjørn, additional, Cuccaro, Annarosa, additional, Del Principe, Maria Ilaria, additional, Kulasekararaj, Austin, additional, Ormazabal-Vélez, Irati, additional, Busca, Alessandro, additional, Demirkan, Fatih, additional, Ijaz, Marriyam, additional, Klimko, Nikolai, additional, Stoma, Igor, additional, Khostelidi, Sofya, additional, Fernández, Noemí, additional, Omrani, Ali S., additional, Bergantim, Rui, additional, De Jonge, Nick, additional, Fouquet, Guillemette, additional, Navrátil, Milan, additional, Abu-Zeinah, Ghaith, additional, Samarkos, Michail, additional, Maertens, Johan, additional, De Ramón, Cristina, additional, Guidetti, Anna, additional, Magyari, Ferenc, additional, González-López, Tomás José, additional, Lahmer, Tobias, additional, Finizio, Olimpia, additional, Ali, Natasha, additional, Pinczés, László Imre, additional, Lavilla-Rubira, Esperanza, additional, Romano, Alessandra, additional, Merelli, Maria, additional, Delia, Mario, additional, Calbacho, Maria, additional, Meletiadis, Joseph, additional, Antić, Darko, additional, Hernández-Rivas, José-Ángel, additional, Marques De Almeida, Joyce, additional, Al-Khabori, Murtadha, additional, Hoenigl, Martin, additional, Tisi, Maria Chiara, additional, Khanna, Nina, additional, Barać, Aleksandra, additional, Eisa, Noha, additional, Di Blasi, Roberta, additional, Liévin, Raphaël, additional, Miranda-Castillo, Carolina, additional, Bahr, Nathan C., additional, Lamure, Sylvain, additional, Papa, Mario Virgilio, additional, Yahya, Ayel, additional, Aujayeb, Avinash, additional, Novák, Jan, additional, Erben, Nurettin, additional, Fernández-Galán, María, additional, Ribera-Santa Susana, José-María, additional, Rinaldi, Ikhwan, additional, Fazzi, Rita, additional, Piedimonte, Monica, additional, Duléry, Rémy, additional, Gonzaga, Yung, additional, Soto-Silva, Andrés, additional, Sapienza, Giuseppe, additional, Serris, Alexandra, additional, Drgoňa, Ľuboš, additional, Groh, Ana, additional, Serrano, Laura, additional, Gavriilaki, Eleni, additional, Tragiannidis, Athanasios, additional, Prattes, Juergen, additional, Coppola, Nicola, additional, Otašević, Vladimir, additional, Mladenović, Miloš, additional, Mitrović, Mirjana, additional, Mišković, Bojana, additional, Jindra, Pavel, additional, Zompi, Sofia, additional, Sacchi, Maria Vittoria, additional, Krekeler, Carolin, additional, Shumilov, Evgenii, additional, Infante, Maria Stefania, additional, García-Bordallo, Daniel, additional, Çolak, Gökçe Melis, additional, Cingolani, Antonella, additional, Mayer, Jiří, additional, Criscuolo, Marianna, additional, Nygaard, Marietta, additional, Hanáková, Michaela, additional, Fianchi, Luana, additional, Ráčil, Zdeněk, additional, Giordano, Antonio, additional, Quattrone, Martina, additional, Bonanni, Matteo, additional, Koehler, Philipp, additional, Rahimli, Laman, additional, Cornely, Oliver A., additional, Pagano, Livio, additional, Martín-Vallejo, Francisco Javier, additional, Zdziarski, Przemyslaw, additional, Zarrinfer, Hossein, additional, Wittig, Jana, additional, Win, Sein, additional, Wai-Man, Vivien, additional, Víšek, Benjamín, additional, Vinh, Donald C., additional, Vehreschild, Maria, additional, Varricchio, Gina, additional, Tsirigotis, Panagiotis, additional, Torres-Tienza, Ana, additional, Tanase, Alina Daniela, additional, Tafuri, Agostino, additional, Stamouli, Maria, additional, Sramek, Jiří, additional, Soussain, Carole, additional, Shirinova, Ayten, additional, Schubert, Jörg, additional, Schalk, Enrico, additional, Salehi, Mohammad Reza, additional, Saleh, Modar, additional, Rosati, Giorgio, additional, Roldán, Elisa, additional, Reizine, Florian, additional, Rêgo, Mayara, additional, Regalado-Artamendi, Isabel, additional, Popova, Marina, additional, Pinto, Fernando, additional, Philippe, Laure, additional, Orth, Hans Martin, additional, Ommen, Hans-Beier, additional, Obr, Aleš, additional, Núñez-Martín-Buitrago, Lucía, additional, Noël, Nicolas, additional, Neuhann, Julia, additional, Nadali, Gianpaolo, additional, Nacov, Julia A., additional, Munhoz Alburquerque, Ana M., additional, Mitra, Maria Enza, additional, Mikulska, Malgorzata, additional, Mellinghoff, Sibylle, additional, Mechtel, Ben, additional, Martín-González, Juan-Alberto, additional, Malak, Sandra, additional, Loureiro-Amigo, Jorge, additional, Lorenzo De La Peña, Lisset, additional, Liberti, Giulia, additional, Landau, Marianne, additional, Lacej, Ira, additional, Kolditz, Martin, additional, Kho, Chi Shan, additional, Khedr, Reham Abdelaziz, additional, Karthaus, Meinolf, additional, Karlsson, Linda Katharina, additional, Jiménez-Lorenzo, María-Josefa, additional, Izuzquiza, Macarena, additional, Hoell-Neugebauer, Baerbel, additional, Herbrecht, Raoul, additional, Heath, Christopher H., additional, Guolo, Fabio, additional, Grothe, Jan, additional, Gerasymchuk, Sergey, additional, García-Sanz, Ramón, additional, García-Poutón, Nicole, additional, Funke, Vaneuza Araújo Moreira, additional, Fung, Monica, additional, Flasshove, Charlotte, additional, Essame, Jenna, additional, Egger, Matthias, additional, Drenou, Bernard, additional, Dragonetti, Giulia, additional, Desole, Maximilian, additional, Della Pepa, Roberta, additional, Deau Fischer, Bénédicte, additional, De Kort, Elizabeth, additional, De Cabo, Erik, additional, Danion, François, additional, Daguindau, Etienne, additional, Cushion, Tania, additional, Cremer, Louise, additional, Cordini, Gregorio, additional, Ciceri, Fabio, additional, Chowdhury, Fazle Rabbi, additional, Chelysheva, Ekaterina, additional, Chauchet, Adrien, additional, Chai, Louis Yi Ann, additional, Ceesay, M. Mansour, additional, Busch, Elena, additional, Brehon, Mathias, additional, Borducchi, Davimar M.M., additional, Booth, Stephen, additional, Bologna, Serge, additional, Berg Venemyr, Caroline, additional, Bailén-Almorox, Rebeca, additional, Antoniadou, Anastasia, additional, Anastasopoulou, Amalia N., additional, and Altuntaş, Fevzi, additional
Published: 2024
Full Text: View/download PDF

14. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Author: Gilead Sciences, Projekt DEAL, Espigado, Ildefonso [0000-0002-4043-6613], Lahmer, Tobias, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Nucci, Marcio, Besson, Caroline, Itri, Federico, Jaksic, Ozren, Čolović, Natasha, Weinbergerová, Barbora, Seval, Guldane Cengiz, Adžić-Vukičević, Tatjana, Szotkowski, Tomáš, Sili, Uluhan, Dargenio, Michelina, van Praet, Jens, van Doesum, Jaap, Schönlein, Martin, Ráčil, Zdeněk, Žák, Pavel, Poulsen, Christian Bjørn, Magliano, Gabriele, Jiménez, Moraima, Bonuomo, Valentina, Piukovics, Klára, Dragonetti, Giulia, Demirkan, Fatih, Blennow, Ola, Valković, Toni, Gomes Da Silva, Maria, Maertens, Johan, Glenthøj, Andreas, Fernández, Noemí, Bergantim, Rui, Verga, Luisa, Petzer, Verena, Omrani, Ali S., Méndez, Gustavo-Adolfo, Machado, Marina, Ledoux, Marie-Pierre, Bailén, Rebeca, Duarte, Rafael F., Del Principe, Maria Ilaria, Farina, Francesca, Martín-Pérez, Sonia, Dávila-Valls, Julio, Marchetti, Monia, Bilgin, Yavuz M., Fracchiolla, Nicola S., Cattaneo, Chiara, Espigado, Ildefonso, Cordoba, Raul, Collins, Graham P., Labrador, Jorge, Falces-Romero, Iker, Prezioso, Lucia, Meers, Stef, Passamonti, Francesco, Buquicchio, Caterina, López-García, Alberto, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Cuccaro, Annarosa, Garcia-Vidal, Carolina, Busca, Alessandro, Navrátil, Milan, de Jonge, Nick, Biernat, Monika M., Guidetti, Anna, Abu-Zeinah, Ghaith, Samarkos, Michail, Anastasopoulou, Amalia, de Ramón, Cristina, González-López, Tomás José, Hoenigl, Martin, Finizio, Olimpia, Pinczés, László Imre, Ali, Natasha, Vena, Antonio, Tascini, Carlo, Stojanoski, Zlate, Merelli, Maria, Emarah, Ziad, Kohn, Milena, Barać, Aleksandra, Mladenović, Miloš, Mišković, Bojana, Ilhan, Osman, Çolak, Gökçe Melis, Čerňan, Martin, Gräfe, Stefanie K., Ammatuna, Emanuele, Hanakova, Michaela, Víšek, Benjamín, Cabirta, Alba, Nordlander, Anna, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Zambrotta, Giovanni Paolo Maria, Wolf, Dominik, Núñez-Martín-Buitrago, Lucía, Arellano, Elena, Aiello, Tommaso Francesco, García-Sanz, Ramón, Prattes, Juergen, Egger, Matthias, Limongelli, Alessandro, Bavastro, Martina, Cvetanoski, Milche, Dibos, Miriam, Rasch, Sebastian, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, Gilead Sciences, Projekt DEAL, Espigado, Ildefonso [0000-0002-4043-6613], Lahmer, Tobias, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Nucci, Marcio, Besson, Caroline, Itri, Federico, Jaksic, Ozren, Čolović, Natasha, Weinbergerová, Barbora, Seval, Guldane Cengiz, Adžić-Vukičević, Tatjana, Szotkowski, Tomáš, Sili, Uluhan, Dargenio, Michelina, van Praet, Jens, van Doesum, Jaap, Schönlein, Martin, Ráčil, Zdeněk, Žák, Pavel, Poulsen, Christian Bjørn, Magliano, Gabriele, Jiménez, Moraima, Bonuomo, Valentina, Piukovics, Klára, Dragonetti, Giulia, Demirkan, Fatih, Blennow, Ola, Valković, Toni, Gomes Da Silva, Maria, Maertens, Johan, Glenthøj, Andreas, Fernández, Noemí, Bergantim, Rui, Verga, Luisa, Petzer, Verena, Omrani, Ali S., Méndez, Gustavo-Adolfo, Machado, Marina, Ledoux, Marie-Pierre, Bailén, Rebeca, Duarte, Rafael F., Del Principe, Maria Ilaria, Farina, Francesca, Martín-Pérez, Sonia, Dávila-Valls, Julio, Marchetti, Monia, Bilgin, Yavuz M., Fracchiolla, Nicola S., Cattaneo, Chiara, Espigado, Ildefonso, Cordoba, Raul, Collins, Graham P., Labrador, Jorge, Falces-Romero, Iker, Prezioso, Lucia, Meers, Stef, Passamonti, Francesco, Buquicchio, Caterina, López-García, Alberto, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Cuccaro, Annarosa, Garcia-Vidal, Carolina, Busca, Alessandro, Navrátil, Milan, de Jonge, Nick, Biernat, Monika M., Guidetti, Anna, Abu-Zeinah, Ghaith, Samarkos, Michail, Anastasopoulou, Amalia, de Ramón, Cristina, González-López, Tomás José, Hoenigl, Martin, Finizio, Olimpia, Pinczés, László Imre, Ali, Natasha, Vena, Antonio, Tascini, Carlo, Stojanoski, Zlate, Merelli, Maria, Emarah, Ziad, Kohn, Milena, Barać, Aleksandra, Mladenović, Miloš, Mišković, Bojana, Ilhan, Osman, Çolak, Gökçe Melis, Čerňan, Martin, Gräfe, Stefanie K., Ammatuna, Emanuele, Hanakova, Michaela, Víšek, Benjamín, Cabirta, Alba, Nordlander, Anna, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Zambrotta, Giovanni Paolo Maria, Wolf, Dominik, Núñez-Martín-Buitrago, Lucía, Arellano, Elena, Aiello, Tommaso Francesco, García-Sanz, Ramón, Prattes, Juergen, Egger, Matthias, Limongelli, Alessandro, Bavastro, Martina, Cvetanoski, Milche, Dibos, Miriam, Rasch, Sebastian, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio
Abstract: The risk for a severe coronavirus disease 2019 (COVID-19) with need for an intensive care unit (ICU) admission in a non-immunocompromised vaccinated population dropped from 5% at the beginning of the pandemic to at least 0.2% and is still decreasing since the omicron strain dominates the COVID-19 pandemic [1]. Beyond the risk factors identified for a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection like male sex, older age, and comorbidities such as cardiovascular disease, lung disease or obesity, patients with a history of malignancy, specifically patients with haematological malignancy, are prone to develop a complicated SARS-CoV-2 infection with need for ICU which is still associated with poorer clinical outcome [2,3,4,5,6,7,8,9,10,11,12,13,14,15]. The circumstances of a widely heterogenous population with regards to the type of haematological malignancy, extent of disease, haematological malignancy treatment history, [16,17,18] and baseline performance status are even more challenging in the environment of an ICU [19]. Although, data referring to critically ill COVID-19 patients regarding treatment strategies and outcome are widely available, data referring to critically ill patients with haematological malignancy are scarce and underreported [20]. The aim of this study is to analyze the epidemiology, risk factors and outcome of patients with haematological malignancy with need for an ICU setting using the data from the large-scale EPICOVIDEHA registry of the European Hematology Association—Scientific Working Group Infectious in Hematology (EHA-SWG) [21].
Published: 2024

15. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022

Author: Arellano-Orden, Elena [0000-0003-0581-8947], Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Weinbergerová, Barbora, Itri, Federico, Dávila-Valls, Julio, Martín-Pérez, Sonia, Glenthøj, Andreas, Hersby, Ditte Stampe, Gomes da Silva, Maria, Nunes Rodrigues, Raquel, López-García, Alberto, Córdoba, Raúl, Bilgin, Yavuz M., Falces-Romero, Iker, El-Ashwah, Shaimaa, Emarah, Ziad, Besson, Caroline, Kohn, Milena, Van Doesum, Jaap, Ammatuna, Emanuele, Marchetti, Monia, Labrador, Jorge, Zambrotta, Giovanni Paolo Maria, Verga, Luisa, Jaksic, Ozren, Nucci, Marcio, Piukovics, Klára, Cabirta-Touzón, Alba, Jiménez, Moraima, Arellano-Orden, Elena, Espigado, Ildefonso, Blennow, Ola, Nordlander, Anna, Meers, Stef, van Praet, Jens, Aiello, Tommaso Francesco, Garcia-Vidal, Carolina, Fracchiolla, Nicola, Sciumè, Mariarita, Seval, Guldane Cengiz, Žák, Pavel, Buquicchio, Caterina, Tascini, Carlo, Gräfe, Stefanie K., Schönlein, Martin, Adžić-Vukičević, Tatjana, Bonuomo, Valentina, Cattaneo, Chiara, Nizamuddin, Summiya, Čerňan, Martin, Plantefeve, Gaëtan, Prin, Romane, Szotkovski, Tomas, Collins, Graham P., Dargenio, Michelina, Petzer, Verena, Wolf, Dominik, Čolović, Natasha, Prezioso, Lucia, Valković, Toni, Passamonti, Francesco, Méndez, Gustavo-Adolfo, Sili, Uluhan, Vena, Antonio, Bavastro, Martina, Limongelli, Alessandro, Duarte, Rafael F., Ledoux, Marie-Pierre, Cvetanoski, Milche, Stojanoski, Zlate, Machado, Marina, Batinić, Josip, Magliano, Gabriele, Biernat, Monika M., Pantić, Nikola, Poulsen, Christian Bjørn, Cuccaro, Annarosa, Del Principe, Maria Ilaria, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Busca, Alessandro, Demirkan, Fatih, Ijaz, Marriyam, Klimko, Nikolai, Stoma, Igor, Khostelidi, Sofya, Fernández, Noemí, Omrani, Ali S, Bergantim, Rui, De Jonge, Nick, Fouquet, Guillemette, Navrátil, Milan, Abu-Zeinah, Ghaith, Samarkos, Michail, Maertens, Johan, De Ramón, Cristina, Guidetti, Anna, Magyari, Ferenc, González-López, Tomás José, Lahmer, Tobias, Finizio, Olimpia, Ali, Natasha, Pinczés, László Imre, Lavilla-Rubira, Esperanza, Romano, Alessandra, Merelli, Maria, Delia, Mario, Calbacho, Maria, Meletiadis, Joseph, Antić, Darko, Hernández-Rivas, José-Ángel, Marques de Almeida, Joyce, Al-Khabori, Murtadha, Hoenigl, Martin, Tisi, Maria Chiara, Khanna, Nina, Barać, Aleksandra, Eisa, Noha, Di Blasi, Roberta, Liévin, Raphaël, Miranda-Castillo, Carolina, Bahr, Nathan C., Lamure, Sylvain, Papa, Mario Virgilio, Yahya, Ayel, Aujayeb, Avinash, Novák, Jan, Erben, Nurettin, Fernández-Galán, María, Ribera-Santa Susana, José-María, Rinaldi, Ikhwan, Fazzi, Rita, Piedimonte, Monica, Duléry, Rémy, Gonzaga, Yung, Soto-Silva, Andrés, Sapienza, Giuseppe, Serris, Alexandra, Drgoňa, Ľuboš, Groh, Ana, Serrano, Laura, Gavriilaki, Eleni, Tragiannidis, Athanasios, Prattes, Juergen, Coppola, Nicola, Otašević, Vladimir, Mladenović, Miloš, Mitrović, Mirjana, Mišković, Bojana, Jindra, Pavel, Zompi, Sofia, Sacchi, Maria Vittoria, Krekeler, Carolin, Infante, Maria Stefania, García-Bordallo, Daniel, Çolak, Gökçe Melis, Mayer, Jiří, Nygaard, Marietta, Hanáková, Michaela, Ráčil, Zdeněk, Bonanni, Matteo, Koehler, Philipp, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, Arellano-Orden, Elena [0000-0003-0581-8947], Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Weinbergerová, Barbora, Itri, Federico, Dávila-Valls, Julio, Martín-Pérez, Sonia, Glenthøj, Andreas, Hersby, Ditte Stampe, Gomes da Silva, Maria, Nunes Rodrigues, Raquel, López-García, Alberto, Córdoba, Raúl, Bilgin, Yavuz M., Falces-Romero, Iker, El-Ashwah, Shaimaa, Emarah, Ziad, Besson, Caroline, Kohn, Milena, Van Doesum, Jaap, Ammatuna, Emanuele, Marchetti, Monia, Labrador, Jorge, Zambrotta, Giovanni Paolo Maria, Verga, Luisa, Jaksic, Ozren, Nucci, Marcio, Piukovics, Klára, Cabirta-Touzón, Alba, Jiménez, Moraima, Arellano-Orden, Elena, Espigado, Ildefonso, Blennow, Ola, Nordlander, Anna, Meers, Stef, van Praet, Jens, Aiello, Tommaso Francesco, Garcia-Vidal, Carolina, Fracchiolla, Nicola, Sciumè, Mariarita, Seval, Guldane Cengiz, Žák, Pavel, Buquicchio, Caterina, Tascini, Carlo, Gräfe, Stefanie K., Schönlein, Martin, Adžić-Vukičević, Tatjana, Bonuomo, Valentina, Cattaneo, Chiara, Nizamuddin, Summiya, Čerňan, Martin, Plantefeve, Gaëtan, Prin, Romane, Szotkovski, Tomas, Collins, Graham P., Dargenio, Michelina, Petzer, Verena, Wolf, Dominik, Čolović, Natasha, Prezioso, Lucia, Valković, Toni, Passamonti, Francesco, Méndez, Gustavo-Adolfo, Sili, Uluhan, Vena, Antonio, Bavastro, Martina, Limongelli, Alessandro, Duarte, Rafael F., Ledoux, Marie-Pierre, Cvetanoski, Milche, Stojanoski, Zlate, Machado, Marina, Batinić, Josip, Magliano, Gabriele, Biernat, Monika M., Pantić, Nikola, Poulsen, Christian Bjørn, Cuccaro, Annarosa, Del Principe, Maria Ilaria, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Busca, Alessandro, Demirkan, Fatih, Ijaz, Marriyam, Klimko, Nikolai, Stoma, Igor, Khostelidi, Sofya, Fernández, Noemí, Omrani, Ali S, Bergantim, Rui, De Jonge, Nick, Fouquet, Guillemette, Navrátil, Milan, Abu-Zeinah, Ghaith, Samarkos, Michail, Maertens, Johan, De Ramón, Cristina, Guidetti, Anna, Magyari, Ferenc, González-López, Tomás José, Lahmer, Tobias, Finizio, Olimpia, Ali, Natasha, Pinczés, László Imre, Lavilla-Rubira, Esperanza, Romano, Alessandra, Merelli, Maria, Delia, Mario, Calbacho, Maria, Meletiadis, Joseph, Antić, Darko, Hernández-Rivas, José-Ángel, Marques de Almeida, Joyce, Al-Khabori, Murtadha, Hoenigl, Martin, Tisi, Maria Chiara, Khanna, Nina, Barać, Aleksandra, Eisa, Noha, Di Blasi, Roberta, Liévin, Raphaël, Miranda-Castillo, Carolina, Bahr, Nathan C., Lamure, Sylvain, Papa, Mario Virgilio, Yahya, Ayel, Aujayeb, Avinash, Novák, Jan, Erben, Nurettin, Fernández-Galán, María, Ribera-Santa Susana, José-María, Rinaldi, Ikhwan, Fazzi, Rita, Piedimonte, Monica, Duléry, Rémy, Gonzaga, Yung, Soto-Silva, Andrés, Sapienza, Giuseppe, Serris, Alexandra, Drgoňa, Ľuboš, Groh, Ana, Serrano, Laura, Gavriilaki, Eleni, Tragiannidis, Athanasios, Prattes, Juergen, Coppola, Nicola, Otašević, Vladimir, Mladenović, Miloš, Mitrović, Mirjana, Mišković, Bojana, Jindra, Pavel, Zompi, Sofia, Sacchi, Maria Vittoria, Krekeler, Carolin, Infante, Maria Stefania, García-Bordallo, Daniel, Çolak, Gökçe Melis, Mayer, Jiří, Nygaard, Marietta, Hanáková, Michaela, Ráčil, Zdeněk, Bonanni, Matteo, Koehler, Philipp, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio
Abstract: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced.
Published: 2024

16. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

Author: Gilead Sciences, Espigado, Ildefonso [0000-0002-4043-6613], El-Ashwah, Shaimaa, Salmanton-García, Jon, Bilgin, Yavuz M., Itri, Federico, Žák, Pavel, Weinbergerová, Barbora, Verga, Luisa, Omrani, Ali S., Silva, Maria Gomes da, Szotkowski, Tomáš, Marchetti, Monia, Buquicchio, Caterina, Nucci, Marcio, Schönlein, Martin, Farina, Francesca, Besson, Caroline, Prezioso, Lucia, Nizamuddin, Summiya, Dávila-Valls, Julio, Martín-Pérez, Sonia, Bonuomo, Valentina, Van Doesum, Jaap, Tisi, Maria Chiara, Passamonti, Francesco, Méndez, Gustavo Adolfo, Meers, Stef, Maertens, Johan, López-García, Alberto, Glenthøj, Andreas, Bonnani, Matteo, Rinaldi, Ikhwan, Ormazabal-Vélez, Irati, Labrador, Jorge, Kulasekararaj, Austin, Espigado, Ildefonso, Demirkan, Fatih, De Jonge, Nick, Collins, Graham P., Calbacho, Maria, Blennow, Ola, Al-Khabori, Murtadha, Adžić-Vukičević, Tatjana, Arellano, Elena, Mišković, Bojana, Mladenović, Miloš, Nordlander, Anna, Ráčil, Zdeněk, Ammatuna, Emanuele, Cordoba, Raul, Hersby, Ditte Stampe, Gräfe, Stefanie, Emarah, Ziad, Hanakova, Michaela, Sacchi, Maria Vittoria, Ijaz, Marriyam, Rahimli, Laman, Nunes Rodrigues, Raquel, Zambrotta, Giovanni Paolo Maria, Marchesi, Francesco, Cornely, Oliver A., Pagano, Livio, Gilead Sciences, Espigado, Ildefonso [0000-0002-4043-6613], El-Ashwah, Shaimaa, Salmanton-García, Jon, Bilgin, Yavuz M., Itri, Federico, Žák, Pavel, Weinbergerová, Barbora, Verga, Luisa, Omrani, Ali S., Silva, Maria Gomes da, Szotkowski, Tomáš, Marchetti, Monia, Buquicchio, Caterina, Nucci, Marcio, Schönlein, Martin, Farina, Francesca, Besson, Caroline, Prezioso, Lucia, Nizamuddin, Summiya, Dávila-Valls, Julio, Martín-Pérez, Sonia, Bonuomo, Valentina, Van Doesum, Jaap, Tisi, Maria Chiara, Passamonti, Francesco, Méndez, Gustavo Adolfo, Meers, Stef, Maertens, Johan, López-García, Alberto, Glenthøj, Andreas, Bonnani, Matteo, Rinaldi, Ikhwan, Ormazabal-Vélez, Irati, Labrador, Jorge, Kulasekararaj, Austin, Espigado, Ildefonso, Demirkan, Fatih, De Jonge, Nick, Collins, Graham P., Calbacho, Maria, Blennow, Ola, Al-Khabori, Murtadha, Adžić-Vukičević, Tatjana, Arellano, Elena, Mišković, Bojana, Mladenović, Miloš, Nordlander, Anna, Ráčil, Zdeněk, Ammatuna, Emanuele, Cordoba, Raul, Hersby, Ditte Stampe, Gräfe, Stefanie, Emarah, Ziad, Hanakova, Michaela, Sacchi, Maria Vittoria, Ijaz, Marriyam, Rahimli, Laman, Nunes Rodrigues, Raquel, Zambrotta, Giovanni Paolo Maria, Marchesi, Francesco, Cornely, Oliver A., and Pagano, Livio
Abstract: Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.
Published: 2024

17. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

Author: Optics COMMIT, Gilead Sciences, Espigado, Ildefonso [0000-0002-4043-6613], Musto, Pellegrino, Salmanton-García, Jon, Sgherza, Nicola, Bergantim, Rui, Farina, Francesca, Glenthøj, Andreas, Cengiz Seval, Guldane, Weinbergerová, Barbora, Bonuomo, Valentina, Bilgin, Yavuz M., van Doesum, Jaap, Jaksic, Ozren, Víšek, Benjamín, Falces-Romero, Iker, Marchetti, Monia, Dávila-Valls, Julio, Martín-Pérez, Sonia, Nucci, Marcio, López-García, Alberto, Itri, Federico, Buquicchio, Caterina, Verga, Luisa, Piukovics, Klára, Navrátil, Milan, Collins, Graham P., Jiménez, Moraima, Fracchiolla, Nicola S., Labrador, Jorge, Prezioso, Lucia, Rossi, Elena, Čolović, Natasha, Meers, Stef, Kulasekararaj, Austin, Cuccaro, Annarosa, Blennow, Ola, Valković, Toni, Sili, Uluhan, Ledoux, Marie-Pierre, Batinić, Josip, Passamonti, Francesco, Machado, Marina, Duarte, Rafael F., Poulsen, Christian Bjørn, Méndez, Gustavo-Adolfo, Espigado, Ildefonso, Demirkan, Fatih, Čerňan, Martin, Cattaneo, Chiara, Petzer, Verena, Magliano, Gabriele, Garcia-Vidal, Carolina, El-Ashwah, Shaimaa, Gomes-Da-Silva, Maria, Vena, Antonio, Ormazabal-Vélez, Irati, van Praet, Jens, Dargenio, Michelina, De-Ramón, Cristina, Del Principe, Maria Ilaria, Marques-De-Almeida, Joyce, Wolf, Dominik, Szotkowski, Tomáš, Obr, Aleš, Çolak, Gökçe Melis, Nordlander, Anna, Izuzquiza, Macarena, Cabirta, Alba, Zambrotta, Giovanni Paolo Maria, Cordoba, Raul, Žák, Pavel, Ammatuna, Emanuele, Mayer, Jiří, Ilhan, Osman, García-Sanz, Ramón, Quattrone, Martina, Arellano, Elena, Nunes-Rodrigues, Raquel, Emarah, Ziad, Aiello, Tommaso Francesco, Hanakova, Michaela, Ráčil, Zdeněk, Bavastro, Martina, Limongelli, Alessandro, Rahimli, Laman, Marchesi, Francesco, Cornely, Oliver A., Pagano, Livio, Optics COMMIT, Gilead Sciences, Espigado, Ildefonso [0000-0002-4043-6613], Musto, Pellegrino, Salmanton-García, Jon, Sgherza, Nicola, Bergantim, Rui, Farina, Francesca, Glenthøj, Andreas, Cengiz Seval, Guldane, Weinbergerová, Barbora, Bonuomo, Valentina, Bilgin, Yavuz M., van Doesum, Jaap, Jaksic, Ozren, Víšek, Benjamín, Falces-Romero, Iker, Marchetti, Monia, Dávila-Valls, Julio, Martín-Pérez, Sonia, Nucci, Marcio, López-García, Alberto, Itri, Federico, Buquicchio, Caterina, Verga, Luisa, Piukovics, Klára, Navrátil, Milan, Collins, Graham P., Jiménez, Moraima, Fracchiolla, Nicola S., Labrador, Jorge, Prezioso, Lucia, Rossi, Elena, Čolović, Natasha, Meers, Stef, Kulasekararaj, Austin, Cuccaro, Annarosa, Blennow, Ola, Valković, Toni, Sili, Uluhan, Ledoux, Marie-Pierre, Batinić, Josip, Passamonti, Francesco, Machado, Marina, Duarte, Rafael F., Poulsen, Christian Bjørn, Méndez, Gustavo-Adolfo, Espigado, Ildefonso, Demirkan, Fatih, Čerňan, Martin, Cattaneo, Chiara, Petzer, Verena, Magliano, Gabriele, Garcia-Vidal, Carolina, El-Ashwah, Shaimaa, Gomes-Da-Silva, Maria, Vena, Antonio, Ormazabal-Vélez, Irati, van Praet, Jens, Dargenio, Michelina, De-Ramón, Cristina, Del Principe, Maria Ilaria, Marques-De-Almeida, Joyce, Wolf, Dominik, Szotkowski, Tomáš, Obr, Aleš, Çolak, Gökçe Melis, Nordlander, Anna, Izuzquiza, Macarena, Cabirta, Alba, Zambrotta, Giovanni Paolo Maria, Cordoba, Raul, Žák, Pavel, Ammatuna, Emanuele, Mayer, Jiří, Ilhan, Osman, García-Sanz, Ramón, Quattrone, Martina, Arellano, Elena, Nunes-Rodrigues, Raquel, Emarah, Ziad, Aiello, Tommaso Francesco, Hanakova, Michaela, Ráčil, Zdeněk, Bavastro, Martina, Limongelli, Alessandro, Rahimli, Laman, Marchesi, Francesco, Cornely, Oliver A., and Pagano, Livio
Abstract: Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 109 /L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.
Published: 2024

18. Type I Interferon Autoantibodies Correlate With Cellular Immune Alterations in Severe COVID-19.

Author: Strunz, Benedikt, Maucourant, Christopher, Mehta, Adi, Wan, Hui, Du, Likun, Sun, Dan, Chen, Puran, Nordlander, Anna, Gao, Yu, Cornillet, Martin, Bister, Jonna, Kvedaraite, Egle, Christ, Wanda, Klingström, Jonas, Geanon, Daniel, Parke, Åsa, Ekwall-Larson, Anna, Rivino, Laura, MacAry, Paul A, and Aleman, Soo
Subjects: COVID-19, COVID-19 pandemic, TYPE I interferons, BACTERIAL diseases, VIRUS diseases
Abstract: Background Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe disease with increased morbidity and mortality among certain risk groups. The presence of autoantibodies against type I interferons (aIFN-Abs) is one mechanism that contributes to severe coronavirus disease 2019 (COVID-19). Methods This study aimed to investigate the presence of aIFN-Abs in relation to the soluble proteome, circulating immune cell numbers, and cellular phenotypes, as well as development of adaptive immunity. Results aIFN-Abs were more prevalent in critical compared to severe COVID-19 but largely absent in the other viral and bacterial infections studied here. The antibody and T-cell response to SARS-CoV-2 remained largely unaffected by the presence aIFN-Abs. Similarly, the inflammatory response in COVID-19 was comparable in individuals with and without aIFN-Abs. Instead, presence of aIFN-Abs had an impact on cellular immune system composition and skewing of cellular immune pathways. Conclusions Our data suggest that aIFN-Abs do not significantly influence development of adaptive immunity but covary with alterations in immune cell numbers. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

19. Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry

Author: Musto, Pellegrino, primary, Salmanton‐García, Jon, additional, Sgherza, Nicola, additional, Bergantim, Rui, additional, Farina, Francesca, additional, Glenthøj, Andreas, additional, Cengiz Seval, Guldane, additional, Weinbergerová, Barbora, additional, Bonuomo, Valentina, additional, Bilgin, Yavuz M., additional, van Doesum, Jaap, additional, Jaksic, Ozren, additional, Víšek, Benjamín, additional, Falces‐Romero, Iker, additional, Marchetti, Monia, additional, Dávila‐Valls, Julio, additional, Martín‐Pérez, Sonia, additional, Nucci, Marcio, additional, López‐García, Alberto, additional, Itri, Federico, additional, Buquicchio, Caterina, additional, Verga, Luisa, additional, Piukovics, Klára, additional, Navrátil, Milan, additional, Collins, Graham P., additional, Jiménez, Moraima, additional, Fracchiolla, Nicola S., additional, Labrador, Jorge, additional, Prezioso, Lucia, additional, Rossi, Elena, additional, Čolović, Natasha, additional, Meers, Stef, additional, Kulasekararaj, Austin, additional, Cuccaro, Annarosa, additional, Blennow, Ola, additional, Valković, Toni, additional, Sili, Uluhan, additional, Ledoux, Marie‐Pierre, additional, Batinić, Josip, additional, Passamonti, Francesco, additional, Machado, Marina, additional, Duarte, Rafael F., additional, Poulsen, Christian Bjørn, additional, Méndez, Gustavo‐Adolfo, additional, Espigado, Ildefonso, additional, Demirkan, Fatih, additional, Čerňan, Martin, additional, Cattaneo, Chiara, additional, Petzer, Verena, additional, Magliano, Gabriele, additional, Garcia‐Vidal, Carolina, additional, El‐Ashwah, Shaimaa, additional, Gomes‐Da‐Silva, Maria, additional, Vena, Antonio, additional, Ormazabal‐Vélez, Irati, additional, van Praet, Jens, additional, Dargenio, Michelina, additional, De‐Ramón, Cristina, additional, Del Principe, Maria Ilaria, additional, Marques‐De‐Almeida, Joyce, additional, Wolf, Dominik, additional, Szotkowski, Tomáš, additional, Obr, Aleš, additional, Çolak, Gökçe Melis, additional, Nordlander, Anna, additional, Izuzquiza, Macarena, additional, Cabirta, Alba, additional, Zambrotta, Giovanni Paolo Maria, additional, Cordoba, Raul, additional, Žák, Pavel, additional, Ammatuna, Emanuele, additional, Mayer, Jiří, additional, Ilhan, Osman, additional, García‐Sanz, Ramón, additional, Quattrone, Martina, additional, Arellano, Elena, additional, Nunes‐Rodrigues, Raquel, additional, Emarah, Ziad, additional, Aiello, Tommaso Francesco, additional, Hanakova, Michaela, additional, Ráčil, Zdeněk, additional, Bavastro, Martina, additional, Limongelli, Alessandro, additional, Rahimli, Laman, additional, Marchesi, Francesco, additional, Cornely, Oliver A., additional, and Pagano, Livio, additional
Published: 2023
Full Text: View/download PDF

20. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

Author: El-Ashwah, Shaimaa, primary, Salmanton-García, Jon, additional, Bilgin, Yavuz M., additional, Itri, Federico, additional, Žák, Pavel, additional, Weinbergerová, Barbora, additional, Verga, Luisa, additional, Omrani, Ali S., additional, Silva, Maria Gomes da, additional, Szotkowski, Tomáš, additional, Marchetti, Monia, additional, Buquicchio, Caterina, additional, Nucci, Marcio, additional, Schönlein, Martin, additional, Farina, Francesca, additional, Besson, Caroline, additional, Prezioso, Lucia, additional, Nizamuddin, Summiya, additional, Dávila-Valls, Julio, additional, Martín-Pérez, Sonia, additional, Bonuomo, Valentina, additional, Van Doesum, Jaap, additional, Tisi, Maria Chiara, additional, Passamonti, Francesco, additional, Méndez, Gustavo-Adolfo, additional, Meers, Stef, additional, Maertens, Johan, additional, López-García, Alberto, additional, Glenthøj, Andreas, additional, Bonnani, Matteo, additional, Rinaldi, Ikhwan, additional, Ormazabal-Vélez, Irati, additional, Labrador, Jorge, additional, Kulasekararaj, Austin, additional, Espigado, Ildefonso, additional, Demirkan, Fatih, additional, De Jonge, Nick, additional, Collins, Graham P., additional, Calbacho, Maria, additional, Blennow, Ola, additional, Al-Khabori, Murtadha, additional, Adžić-Vukičević, Tatjana, additional, Arellano, Elena, additional, Mišković, Bojana, additional, Mladenović, Miloš, additional, Nordlander, Anna, additional, Ráčil, Zdeněk, additional, Ammatuna, Emanuele, additional, Cordoba, Raul, additional, Hersby, Ditte Stampe, additional, Gräfe, Stefanie, additional, Emarah, Ziad, additional, Hanakova, Michaela, additional, Sacchi, Maria Vittoria, additional, Ijaz, Marriyam, additional, Rahimli, Laman, additional, Nunes Rodrigues, Raquel, additional, Zambrotta, Giovanni Paolo Maria, additional, Marchesi, Francesco, additional, Cornely, Oliver A., additional, and Pagano, Livio, additional
Published: 2023
Full Text: View/download PDF

21. Age, Successive Waves, Immunization, and Mortality in Elderly COVID-19 Haematological Patients: EPICOVIDEHA Findings

Author: ROSSI, Giuseppe, primary, SALMANTON-GARCÍA, Jon, additional, CATTANEO, Chiara, additional, MARCHESI, Francesco, additional, DÁVILA-VALLS, Julio, additional, MARTÍN-PÉREZ, Sonia, additional, ITRI, Federico, additional, LÓPEZ-GARCÍA, Alberto, additional, GLENTHØJ, Andreas, additional, SILVA, Maria GOMES DA, additional, BESSON, Caroline, additional, MARCHETTI, Monia, additional, WEINBERGEROVÁ, Barbora, additional, JAKSIC, Ozren, additional, JIMÉNEZ, Moraima, additional, BILGIN, Yavuz M., additional, DOESUM, Jaap VAN, additional, FARINA, Francesca, additional, ŽÁK, Pavel, additional, VERGA, Luisa, additional, COLLINS, Graham P., additional, BONUOMO, Valentina, additional, PRAET, Jens VAN, additional, NUCCI, Marcio, additional, MEERS, Stef, additional, ESPIGADO, Ildefonso, additional, FRACCHIOLLA, Nicola S., additional, VALKOVIĆ, Toni, additional, POULSEN, Christian Bjørn, additional, ČOLOVIĆ, Natasha, additional, DRAGONETTI, Giulia, additional, LEDOUX, Marie-Pierre, additional, TASCINI, Carlo, additional, BUQUICCHIO, Caterina, additional, BLENNOW, Ola, additional, PASSAMONTI, Francesco, additional, MACHADO, Marina, additional, LABRADOR, Jorge, additional, DUARTE, Rafael F., additional, SCHÖNLEIN, Martin, additional, PREZIOSO, Lucia, additional, FALCES-ROMERO, Iker, additional, KULASEKARARAJ, Austin, additional, GARCIA-VIDAL, Carolina, additional, FERNÁNDEZ, Noemí, additional, ABU-ZEINAH, Ghaith, additional, ORMAZABAL-VÉLEZ, Irati, additional, ADŽIĆ-VUKIČEVIĆ, Tatjana, additional, PIUKOVICS, Klára, additional, STOMA, Igor, additional, CUCCARO, Annarosa, additional, MAGLIANO, Gabriele, additional, SZOTKOWSKI, Tomáš, additional, GONZÁLEZ-LÓPEZ, Tomás-José, additional, EL-ASHWAH, Shaimaa, additional, BERGANTIM, Rui, additional, SILI, Uluhan, additional, MAERTENS, Johan, additional, DEMIRKAN, Fatih, additional, RAMÓN, Cristina DE, additional, PETZER, Verena, additional, PRINCIPE, Maria Ilaria DEL, additional, NAVRÁTIL, Milan, additional, DARGENIO, Michelina, additional, SEVAL, Guldane Cengiz, additional, SAMARKOS, Michail, additional, RÁČIL, Zdeněk, additional, PINCZÉS, László Imre, additional, LAHMER, Tobias, additional, BUSCA, Alessandro, additional, MÉNDEZ, Gustavo-Adolfo, additional, VENA, Antonio, additional, BIERNAT, Monika M., additional, MERELLI, Maria, additional, CALBACHO, Maria, additional, BARAĆ, Aleksandra, additional, BAVASTRO, Martina, additional, LIMONGELLI, Alessandro, additional, ILHAN, Osman, additional, WOLF, Dominik, additional, ÇOLAK, Gökçe Melis, additional, GARCÍA-SANZ, Ramón, additional, EMARAH, Ziad, additional, MIŠKOVIĆ, Bojana, additional, GRÄFE, Stefanie, additional, MLADENOVIĆ, Miloš, additional, AIELLO, Tommaso Francesco, additional, NÚÑEZ-MARTÍN-BUITRAGO, Lucía, additional, NORDLANDER, Anna, additional, ARELLANO, Elena, additional, ZAMBROTTA, Giovanni Paolo Maria, additional, AMMATUNA, Emanuele, additional, CABIRTA, Alba, additional, SACCHI, Maria Vittoria, additional, RODRIGUES, Raquel NUNES, additional, HERSBY, Ditte Stampe, additional, HANAKOVA, Michaela, additional, RAHIMLI, Laman, additional, CORDOBA, Raul, additional, CORNELY, Oliver A., additional, and PAGANO, Livio, additional
Published: 2023
Full Text: View/download PDF

22. S292: NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: A REPORT FROMTHE EPICOVIDEHA REGISTRY

Author: Salmanton-García, Jon, primary, Marchesi, Francesco, additional, Gomes Da Silva, Maria, additional, Farina, Francesca, additional, Dávila-Valls, Julio, additional, Bilgin, Yavuz M., additional, Glenthøj, Andreas, additional, Falces-Romero, Iker, additional, Van Doesum, Jaap, additional, Labrador, Jorge, additional, Buquicchio, Caterina, additional, EL-Ashwah, Shaimaa, additional, Petzer, Verena, additional, VAN Praet, Jens, additional, Schönlein, Martin, additional, Dargenio, Michelina, additional, Méndez, Gustavo-Adolfo, additional, Meers, Stef, additional, Itri, Federico, additional, Giordano, Antonio, additional, Imre Pinczes, Laszlo, additional, Espigado, Ildefonso, additional, Stojanoski, Zlate, additional, Lopez-Garcia, Alberto, additional, Prezioso, Lucia, additional, Jaksic, Ozren, additional, Vena, Antonio, additional, Stefano Fracchiolla, Nicola, additional, Jose Gonzalez-Lopez, Tomas, additional, Čolović, Natasa, additional, Delia, Mario, additional, Weinbergerová, Barbora, additional, Marchetti, Monia, additional, Marques DE Almeida, Joyce, additional, Finizio, Olimpia, additional, Besson, Caroline, additional, Biernat, Monika M., additional, Valkovic, Toni, additional, Lahmer, Tobias, additional, Cuccaro, Annarosa, additional, Ormazabal Velez, Irati, additional, Batinic, Josip, additional, Fernández, Noemí, additional, de Jonge, Nick, additional, Tascini, Carlo, additional, Anastasopoulou, Amalia N., additional, Duléry, Rémy, additional, Ilaria DEL Principe, Maria, additional, Plantefeve, Gaëtan, additional, Virgilio Papa, Mario, additional, Nucci, Marcio, additional, Carmen Jimenez Balarezo, Moraima, additional, Aujayeb, Avinash, additional, Angel Hernandez Rivas, Jose, additional, Merelli, Maria, additional, Cattaneo, Chiara, additional, Blennow, Ola, additional, Nordlander, Anna, additional, Cabirta, Alba, additional, Varricchio, Gina, additional, Vittoria Sacchi, Maria, additional, Cordoba, Raul, additional, Arellano, Elena, additional, Gräfe, Stefanie, additional, Wolf, Dominik, additional, Emarah, Ziad, additional, Ammatuna, Emanuele, additional, Stampe Hersby, Ditte, additional, Martín-Pérez, Sonia, additional, Nunes Rodrigues, Raquel, additional, Rahimli, Laman, additional, Pagano, Livio, additional, and Cornely, Oliver A., additional
Published: 2023
Full Text: View/download PDF

23. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Author: Salmanton-García, Jon, primary, Marchesi, Francesco, additional, Gomes da Silva, Maria, additional, Farina, Francesca, additional, Dávila-Valls, Julio, additional, Bilgin, Yavuz M., additional, Glenthøj, Andreas, additional, Falces-Romero, Iker, additional, Van Doesum, Jaap, additional, Labrador, Jorge, additional, Buquicchio, Caterina, additional, El-Ashwah, Shaimaa, additional, Petzer, Verena, additional, Van Praet, Jens, additional, Schönlein, Martin, additional, Dargenio, Michelina, additional, Méndez, Gustavo-Adolfo, additional, Meers, Stef, additional, Itri, Federico, additional, Giordano, Antonio, additional, Pinczés, László Imre, additional, Espigado, Ildefonso, additional, Stojanoski, Zlate, additional, López-García, Alberto, additional, Prezioso, Lucia, additional, Jaksic, Ozren, additional, Vena, Antonio, additional, Fracchiolla, Nicola S., additional, González-López, Tomás José, additional, Colović, Natasa, additional, Delia, Mario, additional, Weinbergerová, Barbora, additional, Marchetti, Monia, additional, Marques de Almeida, Joyce, additional, Finizio, Olimpia, additional, Besson, Caroline, additional, Biernat, Monika M., additional, Valković, Toni, additional, Lahmer, Tobias, additional, Cuccaro, Annarosa, additional, Ormazabal-Vélez, Irati, additional, Batinić, Josip, additional, Fernández, Noemí, additional, De Jonge, Nick, additional, Tascini, Carlo, additional, Anastasopoulou, Amalia N., additional, Duléry, Rémy, additional, Del Principe, Maria Ilaria, additional, Plantefeve, Gaëtan, additional, Papa, Mario Virgilio, additional, Nucci, Marcio, additional, Jiménez, Moraima, additional, Aujayeb, Avinash, additional, Hernández-Rivas, José-Ángel, additional, Merelli, Maria, additional, Cattaneo, Chiara, additional, Blennow, Ola, additional, Nordlander, Anna, additional, Cabirta, Alba, additional, Varricchio, Gina, additional, Sacchi, Maria Vittoria, additional, Cordoba, Raul, additional, Arellano, Elena, additional, Gräfe, Stefanie K., additional, Wolf, Dominik, additional, Emarah, Ziad, additional, Ammatuna, Emanuele, additional, Hersby, Ditte Stampe, additional, Martín-Pérez, Sonia, additional, Nunes Rodrigues, Raquel, additional, Rahimli, Laman, additional, Pagano, Livio, additional, Cornely, Oliver A., additional, Piukovics, Klára, additional, De Ramón, Cristina, additional, Danion, François, additional, Yahya, Ayel, additional, Guidetti, Anna, additional, Garcia-Vidal, Carolina, additional, Sili, Uluhan, additional, Meletiadis, Joseph, additional, De Kort, Elizabeth, additional, Verga, Luisa, additional, Serrano, Laura, additional, Erben, Nurettin, additional, Di Blasi, Roberta, additional, Tragiannidis, Athanasios, additional, Ribera-Santa Susana, José-María, additional, Ommen, Hans-Beier, additional, Busca, Alessandro, additional, Coppola, Nicola, additional, Bergantim, Rui, additional, Dragonetti, Giulia, additional, Criscuolo, Marianna, additional, Fianchi, Luana, additional, Bonanni, Matteo, additional, Soto-Silva, Andrés, additional, Mikulska, Malgorzata, additional, Machado, Marina, additional, Shan Kho, Chi, additional, Hassan, Nazia, additional, Gavriilaki, Eleni, additional, Cordini, Gregorio, additional, Chi, Louis Yi Ann, additional, Eggerer, Matthias, additional, Hoenigl, Martin, additional, Prattes, Juergen, additional, Jiménez-Lorenzo, María-Josefa, additional, Zompi, Sofia, additional, Zambrotta, Giovanni Paolo Maria, additional, Çolak, Gökçe Melis, additional, García-Poutón, Nicole, additional, Aiello, Tommaso Francesco, additional, Prin, Romane, additional, Stamouli, Maria, additional, and Samarkos, Michail, additional
Published: 2023
Full Text: View/download PDF

24. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies:a report from the EPICOVIDEHA registry

Author: Nucci, Marcio, Jiménez, Moraima, Aujayeb, Avinash, Hernández-Rivas, José Ángel, Merelli, Maria, Cattaneo, Chiara, Blennow, Ola, Nordlander, Anna, Cabirta, Alba, Varricchio, Gina, Sacchi, Maria Vittoria, Cordoba, Raul, Arellano, Elena, Gräfe, Stefanie K., Wolf, Dominik, Emarah, Ziad, Ammatuna, Emanuele, Hersby, Ditte Stampe, Martin-perez, Sonia, Rodrigues, Raquel Nunes, Rahimli, Laman, Pagano, Livio, Cornely, Oliver A., Nucci, Marcio, Jiménez, Moraima, Aujayeb, Avinash, Hernández-Rivas, José Ángel, Merelli, Maria, Cattaneo, Chiara, Blennow, Ola, Nordlander, Anna, Cabirta, Alba, Varricchio, Gina, Sacchi, Maria Vittoria, Cordoba, Raul, Arellano, Elena, Gräfe, Stefanie K., Wolf, Dominik, Emarah, Ziad, Ammatuna, Emanuele, Hersby, Ditte Stampe, Martin-perez, Sonia, Rodrigues, Raquel Nunes, Rahimli, Laman, Pagano, Livio, and Cornely, Oliver A.
Abstract: Background Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan–Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448–4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619–8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093–0.732) and obesity (aOR 0.105, 95%CI 0.014–0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was o, Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods: This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan–Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings: A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448–4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619–8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093–0.732) and obesity (aOR 0.105, 95%CI 0.014–0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the m
Published: 2023

25. Outcome of COVID-19 in allogeneic stem cell transplant recipients:Results from the EPICOVIDEHA registry

Author: Busca, Alessandro, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Seval, Guldane Cengiz, Van Doesum, Jaap, De Jonge, Nick, Bahr, Nathan C., Maertens, Johan, Meletiadis, Joseph, Fracchiolla, Nicola S., Weinbergerová, Barbora, Verga, Luisa, Ráčil, Zdeněk, Jiménez, Moraima, Glenthøj, Andreas, Blennow, Ola, Tanase, Alina Daniela, Schönlein, Martin, Prezioso, Lucia, Khanna, Nina, Duarte, Rafael F., Žák, Pavel, Nucci, Marcio, Machado, Marina, Kulasekararaj, Austin, Espigado, Ildefonso, De Kort, Elizabeth, Ribera-Santa Susana, José María, Marchetti, Monia, Magliano, Gabriele, Falces-Romero, Iker, Ilhan, Osman, Ammatuna, Emanuele, Zompi, Sofia, Tsirigotis, Panagiotis, Antoniadou, Anastasia, Zambrotta, Giovanni Paolo Maria, Nordlander, Anna, Karlsson, Linda Katharina, Hanakova, Michaela, Dragonetti, Giulia, Cabirta, Alba, Berg Venemyr, Caroline, Gräfe, Stefanie, Van Praet, Jens, Tragiannidis, Athanasios, Petzer, Verena, López-García, Alberto, Itri, Federico, Groh, Ana, Gavriilaki, Eleni, Dargenio, Michelina, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, Busca, Alessandro, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Seval, Guldane Cengiz, Van Doesum, Jaap, De Jonge, Nick, Bahr, Nathan C., Maertens, Johan, Meletiadis, Joseph, Fracchiolla, Nicola S., Weinbergerová, Barbora, Verga, Luisa, Ráčil, Zdeněk, Jiménez, Moraima, Glenthøj, Andreas, Blennow, Ola, Tanase, Alina Daniela, Schönlein, Martin, Prezioso, Lucia, Khanna, Nina, Duarte, Rafael F., Žák, Pavel, Nucci, Marcio, Machado, Marina, Kulasekararaj, Austin, Espigado, Ildefonso, De Kort, Elizabeth, Ribera-Santa Susana, José María, Marchetti, Monia, Magliano, Gabriele, Falces-Romero, Iker, Ilhan, Osman, Ammatuna, Emanuele, Zompi, Sofia, Tsirigotis, Panagiotis, Antoniadou, Anastasia, Zambrotta, Giovanni Paolo Maria, Nordlander, Anna, Karlsson, Linda Katharina, Hanakova, Michaela, Dragonetti, Giulia, Cabirta, Alba, Berg Venemyr, Caroline, Gräfe, Stefanie, Van Praet, Jens, Tragiannidis, Athanasios, Petzer, Verena, López-García, Alberto, Itri, Federico, Groh, Ana, Gavriilaki, Eleni, Dargenio, Michelina, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio
Abstract: Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.
Published: 2023

26. Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Author: Marchetti, Monia, Salmanton-García, Jon, El-Ashwah, Shaimaa, Verga, Luisa, Itri, Federico, Ráčil, Zdeněk, Dávila-Valls, Julio, Martín-Pérez, Sonia, Van Doesum, Jaap, Passamonti, Francesco, Abu-Zeinah, Ghaith, Farina, Francesca, López-García, Alberto, Dragonetti, Giulia, Cattaneo, Chiara, Gomes Da Silva, Maria, Bilgin, Yavuz M, Žák, Pavel, Petzer, Verena, Glenthøj, Andrea, Espigado, Ildefonso, Buquicchio, Caterina, Bonuomo, Valentina, Prezioso, Lucia, Meers, Stef, Duarte, Rafael, Bergantim, Rui, Jaksic, Ozren, Čolović, Natasha, Blennow, Ola, Cernan, Martin, Schönlein, Martin, Samarkos, Michail, Mitra, Maria Enza, Magliano, Gabriele, Maertens, Johan, Ledoux, Marie-Pierre, Jiménez, Moraima, Demirkan, Fatih, Collins, Graham P, Cabirta, Alba, Gräfe, Stefanie K, Nordlander, Anna, Wolf, Dominik, Arellano, Elena, Cordoba, Raul, Hanakova, Michaela, Zambrotta, Giovanni Paolo Maria, Nunes Rodrigues, Raquel, Limberti, Giulia, Marchesi, Francesco, Cornely, Oliver A, Pagano, Livio, Pagano, Livio (ORCID:0000-0001-8287-928X), Marchetti, Monia, Salmanton-García, Jon, El-Ashwah, Shaimaa, Verga, Luisa, Itri, Federico, Ráčil, Zdeněk, Dávila-Valls, Julio, Martín-Pérez, Sonia, Van Doesum, Jaap, Passamonti, Francesco, Abu-Zeinah, Ghaith, Farina, Francesca, López-García, Alberto, Dragonetti, Giulia, Cattaneo, Chiara, Gomes Da Silva, Maria, Bilgin, Yavuz M, Žák, Pavel, Petzer, Verena, Glenthøj, Andrea, Espigado, Ildefonso, Buquicchio, Caterina, Bonuomo, Valentina, Prezioso, Lucia, Meers, Stef, Duarte, Rafael, Bergantim, Rui, Jaksic, Ozren, Čolović, Natasha, Blennow, Ola, Cernan, Martin, Schönlein, Martin, Samarkos, Michail, Mitra, Maria Enza, Magliano, Gabriele, Maertens, Johan, Ledoux, Marie-Pierre, Jiménez, Moraima, Demirkan, Fatih, Collins, Graham P, Cabirta, Alba, Gräfe, Stefanie K, Nordlander, Anna, Wolf, Dominik, Arellano, Elena, Cordoba, Raul, Hanakova, Michaela, Zambrotta, Giovanni Paolo Maria, Nunes Rodrigues, Raquel, Limberti, Giulia, Marchesi, Francesco, Cornely, Oliver A, Pagano, Livio, and Pagano, Livio (ORCID:0000-0001-8287-928X)
Abstract: Background:Patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPN) typically incur high rates of infections and both drugs and comorbidities may modulate infection risk. Objectives:The present study aims to assess the effect of immunosuppressive agents on clinical outcomes of MPN patients affected by the coronavirus disease 2019 (COVID-19). Design:This is an observational study. Methods:We specifically searched and analyzed MPN patients collected by EPICOVIDEHA online registry, which includes individuals with hematological malignancies diagnosed with COVID-19 since February 2020. Results:Overall, 398 patients with MPN were observed for a median of 76 days [interquartile range (IQR): 19-197] after detection of SARS-CoV2 infection. Median age was 69 years (IQR: 58-77) and 183 individuals (46%) had myelofibrosis (MF). Overall, 121 patients (30%) of the whole cohort received immunosuppressive therapies including steroids, immunomodulatory drugs, or JAK inhibitors. Hospitalization and consecutive admission to intensive care unit was required in 216 (54%) and 53 patients (13%), respectively. Risk factors for hospital admission were identified by multivariable logistic regression and include exposure to immunosuppressive therapies [odds ratio (OR): 2.186; 95% confidence interval (CI): 1.357-3.519], age > 70 years, and comorbidities. The fatality rate was 22% overall and the risk of death was independently increased by age > 70 years [hazard ratio (HR): 2.191; 95% CI: 1.363-3.521], previous comorbidities, and exposure to immunosuppressive therapies before the infection (HR: 2.143; 95% CI: 1.363-3.521). Conclusion:COVID-19 infection led to a particularly dismal outcome in MPN patients receiving immunosuppressive agents or reporting multiple comorbidities. Therefore, specific preventive strategies need to be tailored for such individuals. Plain language summaryEPICOVIDEHA registry reports inferior outcomes of COVID-19 in patients with Philadelphia
Published: 2023

27. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Author: Gilead Sciences, Salmanton-García, Jon, Marchesi, Francesco, Silva, Maria Gomes da, Farina, Francesca, Dávila-Valls, Julio, Bilgin, Yavuz M., Glenthøj, Andreas, Falces-Romero, Iker, Doesum, Jaap van, Labrador, Jorge, Buquicchio, Caterina, El-Ashwah, Shaimaa, Petzer, Verena, Van Praet, Jens, Schönlein, Martin, Dargenio, Michelina, Méndez, Gustavo-Adolfo, Meers, Stef, Itri, Federico, Giordano, Antonio, Pinczés, László Imre, Espigado, Ildefonso, Stojanoski, Zlate, López-García, Alberto, Prezioso, Lucia, Jaksic, Ozren, Vena, Antonio, Fracchiolla, Nicola S., González-López, Tomás José, Čolović, Natasa, Delia, Mario, Weinbergerová, Barbora, Marchetti, Monia, Marqués de Almeida, Joyce, Finizio, Olimpia, Besson, Caroline, Biernat, Monika M., Valković, Toni, Lahmer, Tobias, Cuccaro, Annarosa, Ormazabal-Vélez, Irati, Batinić, Josip, Fernández, Noemí, Jonge, Nick de, Tascini, Carlo, Anastasopoulou, Amalia N., Duléry, Rémy, Príncipe, María Ilaria del, Plantefeve, Gaëtan, Papa, Mario Virgilio, Nucci, Marcio, Jiménez, Moraima, Aujayeb, Avinash, Hernández-Rivas, José Ángel, Merelli, Maria, Cattaneo, Chiara, Blennow, Ola, Nordlander, Anna, Cabirta, Alba, Varricchio, Gina, Sacchi, Maria Vittoria, Córdoba, Raúl, Arellano-Orden, Elena, Gräfe, Stefanie, Wolf, Dominik, Emarah, Ziad, Ammatuna, Emanuele, Hersby, Ditte Stampe, Martín-Pérez, Sonia, Nunes-Rodrigues, Raquel, Rahimli, Laman, Pagano, Livio, Cornely, Oliver A., EPICOVIDEHA registry, Gilead Sciences, Salmanton-García, Jon, Marchesi, Francesco, Silva, Maria Gomes da, Farina, Francesca, Dávila-Valls, Julio, Bilgin, Yavuz M., Glenthøj, Andreas, Falces-Romero, Iker, Doesum, Jaap van, Labrador, Jorge, Buquicchio, Caterina, El-Ashwah, Shaimaa, Petzer, Verena, Van Praet, Jens, Schönlein, Martin, Dargenio, Michelina, Méndez, Gustavo-Adolfo, Meers, Stef, Itri, Federico, Giordano, Antonio, Pinczés, László Imre, Espigado, Ildefonso, Stojanoski, Zlate, López-García, Alberto, Prezioso, Lucia, Jaksic, Ozren, Vena, Antonio, Fracchiolla, Nicola S., González-López, Tomás José, Čolović, Natasa, Delia, Mario, Weinbergerová, Barbora, Marchetti, Monia, Marqués de Almeida, Joyce, Finizio, Olimpia, Besson, Caroline, Biernat, Monika M., Valković, Toni, Lahmer, Tobias, Cuccaro, Annarosa, Ormazabal-Vélez, Irati, Batinić, Josip, Fernández, Noemí, Jonge, Nick de, Tascini, Carlo, Anastasopoulou, Amalia N., Duléry, Rémy, Príncipe, María Ilaria del, Plantefeve, Gaëtan, Papa, Mario Virgilio, Nucci, Marcio, Jiménez, Moraima, Aujayeb, Avinash, Hernández-Rivas, José Ángel, Merelli, Maria, Cattaneo, Chiara, Blennow, Ola, Nordlander, Anna, Cabirta, Alba, Varricchio, Gina, Sacchi, Maria Vittoria, Córdoba, Raúl, Arellano-Orden, Elena, Gräfe, Stefanie, Wolf, Dominik, Emarah, Ziad, Ammatuna, Emanuele, Hersby, Ditte Stampe, Martín-Pérez, Sonia, Nunes-Rodrigues, Raquel, Rahimli, Laman, Pagano, Livio, Cornely, Oliver A., and EPICOVIDEHA registry
Abstract: [Background] Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients., [Methods] This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan–Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir., [Findings] A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448–4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619–8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093–0.732) and obesity (aOR 0.105, 95%CI 0.014–0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration., [Interpretation] Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir.
Published: 2023

28. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

Author: Gilead Sciences, Salmanton-García, Jon, Marchesi, Francesco, Koehler, Philipp, Weinbergerová, Barbora, Čolović, Natasa, Falces-Romero, Iker, Buquicchio, Caterina, Farina, Francesca, Praet, Jens van, Biernat, Monika M., Itri, Federico, Prezioso, Lucia, Tascini, Carlo, Vena, Antonio, Romano, Alessandra, Delia, Mario, Dávila-Valls, Julio, Martín-Pérez, Sonia, Lavilla-Rubira, Esperanza, Adžić-vukičević, Tatjana, García-Bordallo, Daniel, López-García, Alberto, Criscuolo, Mariana, Petzer, Verena, Fracchiolla, Nicola S., Espigado, Ildefonso, Sili, Uluhan, Meers, Stef, Erben, Nurettin, Cattaneo, Chiara, Tragiannidis, Athanasios, Gavriilaki, Eleni, Schönlein, Martin, Mitrovic, Mirjana, Pantic, Nikola, Merelli, Maria, Labrador, Jorge, Hernández-Rivas, José Ángel, Glenthøj, Andreas, Fouquet, Guillemette, Príncipe, María Ilaria del, Dargenio, Michelina, Calbacho, María, Besson, Caroline, Kohn, Milena, Gräfe, Stefanie, Hersby, Ditte Stampe, Arellano-Orden, Elena, Çolak, Gökçe Melis, Wolf, Dominik, Marchetti, Monia, Nordlander, Anna, Blennow, Ola, Córdoba, Raúl, Mišković, Bojana, Mladenović, Miloš, Bavastro, Martina, Limongelli, Alessandro, Rahimli, Laman, Pagano, Livio, Cornely, Oliver A., Gilead Sciences, Salmanton-García, Jon, Marchesi, Francesco, Koehler, Philipp, Weinbergerová, Barbora, Čolović, Natasa, Falces-Romero, Iker, Buquicchio, Caterina, Farina, Francesca, Praet, Jens van, Biernat, Monika M., Itri, Federico, Prezioso, Lucia, Tascini, Carlo, Vena, Antonio, Romano, Alessandra, Delia, Mario, Dávila-Valls, Julio, Martín-Pérez, Sonia, Lavilla-Rubira, Esperanza, Adžić-vukičević, Tatjana, García-Bordallo, Daniel, López-García, Alberto, Criscuolo, Mariana, Petzer, Verena, Fracchiolla, Nicola S., Espigado, Ildefonso, Sili, Uluhan, Meers, Stef, Erben, Nurettin, Cattaneo, Chiara, Tragiannidis, Athanasios, Gavriilaki, Eleni, Schönlein, Martin, Mitrovic, Mirjana, Pantic, Nikola, Merelli, Maria, Labrador, Jorge, Hernández-Rivas, José Ángel, Glenthøj, Andreas, Fouquet, Guillemette, Príncipe, María Ilaria del, Dargenio, Michelina, Calbacho, María, Besson, Caroline, Kohn, Milena, Gräfe, Stefanie, Hersby, Ditte Stampe, Arellano-Orden, Elena, Çolak, Gökçe Melis, Wolf, Dominik, Marchetti, Monia, Nordlander, Anna, Blennow, Ola, Córdoba, Raúl, Mišković, Bojana, Mladenović, Miloš, Bavastro, Martina, Limongelli, Alessandro, Rahimli, Laman, Pagano, Livio, and Cornely, Oliver A.
Abstract: [Introduction] Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections and decrease hospitalisation and mortality rates. Nirmatrelvir/ritonavir was authorised in Europe in December 2021, whereas molnupiravir is not yet licensed in Europe as of February 2022. Molnupiravir may be an alternative to nirmatrelvir/ritonavir because it is associated with fewer drug-drug interactions and contraindications. A caveat for molnupiravir is the mode of action induces viral mutations. Mortality rate reduction with molnupiravir was less pronounced than that with nirmatrelvir/ritonavir in patients without haematological malignancy. Little is known about the comparative efficacy of the two drugs in patients with haematological malignancy at high-risk of severe COVID-19. Thus, molnupiravir and nirmatrelvir/ritonavir were compared in a cohort of patients with haematological malignancies., [Methods] Clinical data from patients treated with molnupiravir or nirmatrelvir/ritonavir monotherapy for COVID-19 were retrieved from the EPICOVIDEHA registry. Patients treated with molnupiravir were matched by sex, age (±10 years), and severity of baseline haematological malignancy to controls treated with nirmatrelvir/ritonavir., [Results] A total of 116 patients receiving molnupiravir for the clinical management of COVID-19 were matched to an equal number of controls receiving nirmatrelvir/ritonavir. In each of the groups, 68 (59%) patients were male; with a median age of 64 years (interquartile range [IQR] 53-74) for molnupiravir recipients and 64 years (IQR 54-73) for nirmatrelvir/ritonavir recipients; 56.9% (n=66) of the patients had controlled baseline haematological malignancy, 12.9% (n=15) had stable disease, and 30.2% (n=35) had active disease at COVID-19 onset in each group. During COVID-19 infection, one third of patients from each group were admitted to hospital. Although a similar proportion of patients in the two groups were vaccinated (molnupiravir n=77, 66% vs. nirmatrelvir/ritonavir n=87, 75%), more of those treated with nirmatrelvir/ritonavir had received four vaccine doses (n=27, 23%) compared with those treated with molnupiravir (n=5, 4%) (P<0.001). No differences were detected in COVID-19 severity (P=0.39) or hospitalisation (P=1.0). No statistically significant differences were identified in overall mortality rate (P=0.78) or survival probability (d30 P=0.19, d60 P=0.67, d90 P=0.68, last day of follow up P=0.68). Deaths were either attributed to COVID-19, or the infection was judged by the treating physician to have contributed to death., [Conclusions] Hospitalisation and mortality rates with molnupiravir were comparable to those with nirmatrelvir/ritonavir in high-risk patients with haematological malignancies and COVID-19. Molnupiravir is a plausible alternative to nirmatrelvir/ritonavir for COVID-19 treatment in patients with haematological malignancy.
Published: 2023

29. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Author: Gilead Sciences, Busca, Alessandro, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Cengiz-Seval, Guldane, Doesum, Jaap van, Jonge, Nick de, Bahr, Nathan C., Maertens, Johan, Meletiadis, Joseph, Fracchiolla, Nicola S., Weinbergerová, Barbora, Verga, Luisa, Ráčil, Zdeněk, Jiménez, Moraima, Glenthøj, Andreas, Blennow, Ola, Tanase, Alina Daniela, Schönlein, Martin, Prezioso, Lucia, Khanna, Nina, Duarte, Rafael F., Žák, Pavel, Nucci, Marcio, Machado, Marina, Kulasekararaj, Austin, Espigado, Ildefonso, Kort, Elizabeth de, Ribera-Santa Susana, José-María, Marchetti, Monia, Magliano, Gabriele, Falces-Romero, Iker, Ilhan, Osman, Ammatuna, Emanuele, Zompi, Sofia, Tsirigotis, Panagiotis, Antoniadou, Anastasia, Zambrotta, Giovanni Paolo Maria, Nordlander, Anna, Karlsson, Linda Katharina, Hanakova, Michaela, Dragonetti, Giulia, Cabirta, Alba, Berg Venemyr, Caroline, Gräfe, Stefanie, Praet, Jens van, Tragiannidis, Athanasios, Petzer, Verena, López-García, Alberto, Itri, Federico, Groh, Ana, Gavriilaki, Eleni, Dargenio, Michelina, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, EPICOVIDEHA Consortium, Gilead Sciences, Busca, Alessandro, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Cengiz-Seval, Guldane, Doesum, Jaap van, Jonge, Nick de, Bahr, Nathan C., Maertens, Johan, Meletiadis, Joseph, Fracchiolla, Nicola S., Weinbergerová, Barbora, Verga, Luisa, Ráčil, Zdeněk, Jiménez, Moraima, Glenthøj, Andreas, Blennow, Ola, Tanase, Alina Daniela, Schönlein, Martin, Prezioso, Lucia, Khanna, Nina, Duarte, Rafael F., Žák, Pavel, Nucci, Marcio, Machado, Marina, Kulasekararaj, Austin, Espigado, Ildefonso, Kort, Elizabeth de, Ribera-Santa Susana, José-María, Marchetti, Monia, Magliano, Gabriele, Falces-Romero, Iker, Ilhan, Osman, Ammatuna, Emanuele, Zompi, Sofia, Tsirigotis, Panagiotis, Antoniadou, Anastasia, Zambrotta, Giovanni Paolo Maria, Nordlander, Anna, Karlsson, Linda Katharina, Hanakova, Michaela, Dragonetti, Giulia, Cabirta, Alba, Berg Venemyr, Caroline, Gräfe, Stefanie, Praet, Jens van, Tragiannidis, Athanasios, Petzer, Verena, López-García, Alberto, Itri, Federico, Groh, Ana, Gavriilaki, Eleni, Dargenio, Michelina, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, and EPICOVIDEHA Consortium
Abstract: Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.
Published: 2023

30. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

Author: Gilead Sciences, Rossi, Giuseppe, Salmanton-García, Jon, Cattaneo, Chiara, Marchesi, Francesco, Dávila-Valls, Julio, Martín-Pérez, Sonia, Itri, Federico, López-García, Alberto, Glenthøj, Andreas, Silva, Maria Gomes da, Besson, Caroline, Marchetti, Monia, Weinbergerová, Barbora, Jaksic, Ozren, Jiménez, Moraima, Bilgin, Yavuz M., Doesum, Jaap van, Farina, Francesca, Žák, Pavel, Verga, Luisa, Collins, Graham P., Bonuomo, Valentina, Praet, Jens van, Nucci, Marcio, Meers, Stef, Espigado, Ildefonso, Fracchiolla, Nicola S., Valković, Toni, Poulsen, Christian Bjørn, Čolović, Natasha, Dragonetti, Giulia, Ledoux, Marie-Pierre, Tascini, Carlo, Buquicchio, Caterina, Blennow, Ola, Passamonti, Francesco, Machado, Marina, Labrador, Jorge, Duarte, Rafael F., Schönlein, Martin, Prezioso, Lucia, Falces-Romero, Iker, Kulasekararaj, Austin, García-Vidal, Carolina, Fernández, Noemí, Abu-Zeinah, Ghaith, Ormazabal-Vélez, Irati, Adžić-Vukičević, Tatjana, Piukovics, Klára, Stoma, Igor, Cuccaro, Annarosa, Magliano, Gabriele, Szotkowski, Tomáš, González-López, Tomás José, El-Ashwah, Shaimaa, Bergantim, Rui, Sili, Uluhan, Maertens, Johan, Demirkan, Fatih, Ramón, Cristina de, Petzer, Verena, Príncipe, María Ilaria del, Navrátil, Milan, Dargenio, Michelina, Cengiz Seval, Guldane, Samarkos, Michail, Ráčil, Zdeněk, Pinczés, László Imre, Lahmer, Tobias, Busca, Alessandro, Méndez, Gustavo-Adolfo, Vena, Antonio, Biernat, Monika M., Merelli, Maria, Calbacho, Maria, Barać, Aleksandra, Bavastro, Martina, Limongelli, Alessandro, Ilhan, Osman, Wolf, Dominik, Çolak, Gökçe Melis, García-Sanz, Ramón, Emarah, Ziad, Mišković, Bojana, Gräfe, Stefanie, Mladenović, Miloš, Aiello, Tommaso Francesco, Núñez-Martín-Buitrago, Lucía, Nordlander, Anna, Arellano-Orden, Elena, Zambrotta, Giovanni Paolo Maria, Ammatuna, Emanuele, Cabirta, Alba, Sacchi, Maria Vittoria, Nunes-Rodrigues, Raquel, Hersby, Ditte Stampe, Hanakova, Michaela, Rahimli, Laman, Córdoba, Raúl, Cornely, Oliver A., Pagano, Livio, Collaborators, Gilead Sciences, Rossi, Giuseppe, Salmanton-García, Jon, Cattaneo, Chiara, Marchesi, Francesco, Dávila-Valls, Julio, Martín-Pérez, Sonia, Itri, Federico, López-García, Alberto, Glenthøj, Andreas, Silva, Maria Gomes da, Besson, Caroline, Marchetti, Monia, Weinbergerová, Barbora, Jaksic, Ozren, Jiménez, Moraima, Bilgin, Yavuz M., Doesum, Jaap van, Farina, Francesca, Žák, Pavel, Verga, Luisa, Collins, Graham P., Bonuomo, Valentina, Praet, Jens van, Nucci, Marcio, Meers, Stef, Espigado, Ildefonso, Fracchiolla, Nicola S., Valković, Toni, Poulsen, Christian Bjørn, Čolović, Natasha, Dragonetti, Giulia, Ledoux, Marie-Pierre, Tascini, Carlo, Buquicchio, Caterina, Blennow, Ola, Passamonti, Francesco, Machado, Marina, Labrador, Jorge, Duarte, Rafael F., Schönlein, Martin, Prezioso, Lucia, Falces-Romero, Iker, Kulasekararaj, Austin, García-Vidal, Carolina, Fernández, Noemí, Abu-Zeinah, Ghaith, Ormazabal-Vélez, Irati, Adžić-Vukičević, Tatjana, Piukovics, Klára, Stoma, Igor, Cuccaro, Annarosa, Magliano, Gabriele, Szotkowski, Tomáš, González-López, Tomás José, El-Ashwah, Shaimaa, Bergantim, Rui, Sili, Uluhan, Maertens, Johan, Demirkan, Fatih, Ramón, Cristina de, Petzer, Verena, Príncipe, María Ilaria del, Navrátil, Milan, Dargenio, Michelina, Cengiz Seval, Guldane, Samarkos, Michail, Ráčil, Zdeněk, Pinczés, László Imre, Lahmer, Tobias, Busca, Alessandro, Méndez, Gustavo-Adolfo, Vena, Antonio, Biernat, Monika M., Merelli, Maria, Calbacho, Maria, Barać, Aleksandra, Bavastro, Martina, Limongelli, Alessandro, Ilhan, Osman, Wolf, Dominik, Çolak, Gökçe Melis, García-Sanz, Ramón, Emarah, Ziad, Mišković, Bojana, Gräfe, Stefanie, Mladenović, Miloš, Aiello, Tommaso Francesco, Núñez-Martín-Buitrago, Lucía, Nordlander, Anna, Arellano-Orden, Elena, Zambrotta, Giovanni Paolo Maria, Ammatuna, Emanuele, Cabirta, Alba, Sacchi, Maria Vittoria, Nunes-Rodrigues, Raquel, Hersby, Ditte Stampe, Hanakova, Michaela, Rahimli, Laman, Córdoba, Raúl, Cornely, Oliver A., Pagano, Livio, and Collaborators
Abstract: [Objectives] Elderly patients with hematologic malignancies face the highest risk of severe COVID-19 outcomes. The infection's impact on different age groups remains unstudied in detail., [Methods] We analyzed elderly patients (age groups: 65-70, 71-75, 76-80, and >80 years old) with hematologic malignancies included in the EPICOVIDEHA registry between January 2020 and July 2022. Univariable and multivariable Cox regression models were conducted to identify factors influencing death in COVID-19 patients with hematological malignancy., [Results] The study included data from 3,603 elderly patients (aged 65 or older) with hematological malignancy, with a majority being male (58.1%) and a significant proportion having comorbidities. The patients were divided into four age groups, and the analysis assessed COVID-19 outcomes, vaccination status, and other variables in relation to age and pandemic waves. The 90-day survival rate for patients with COVID-19 was 71.2%, with significant differences between groups. The pandemic waves had varying impacts, with the first wave affecting patients over 80 years old, the second being more severe in 65-70, and the third being the least severe in all age groups. Factors contributing to 90-day mortality included age, comorbidities, lymphopenia, active malignancy, acute leukemia, less than three vaccine doses, severe COVID-19, and using only corticosteroids as treatment., [Conclusion] These data underscore the heterogeneity of elderly hematological patients, highlight the different impacts of COVID-19 waves and the pivotal importance of vaccination, and may help in planning future healthcare efforts.
Published: 2023

31. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

Author: Doesum, Jaap van, Salmanton-García, Jon, Marchesi, Francesco, Blasi, Roberta di, Falces-Romero, Iker, Cabirta, Alba, Farina, Francesca, Besson, Caroline, Weinbergerová, Barbora, Praet, Jens van, Schönlein, Martin, López-García, Alberto, Lamure, Sylvain, Guidetti, Anna, Ramón, Cristina de, Batinić, Josip, Gavriilaki, Eleni, Tragiannidis, Athanasios, Tisi, Maria Chiara, Plantefeve, Gaëtan, Petzer, Verena, Ormazabal-Vélez, Irati, Marques de Almedia, Joyce, Marchetti, Monia, Maertens, Johan, Machado, Marina, Kulasekararaj, Austin G., Hernández-Rivas, José Ángel, Gomes Da Silva, María, Fernández, Noemí, Espigado, Ildefonso, Drgona, Lubos, Dragonetti, Giulia, Metafuni, Elisabetta, Calbacho, María, Blennow, Ola, Wolf, Dominik, Anrooij, Bjorn van, Nunes-Rodrigues, Raquel, Nordlander, Anna, Martín-González, Juan-Alberto, Lievin, Raphaël, Jiménez, Moraima, Gräfe, Stefanie, García-Sanz, Ramón, Córdoba, Raúl, Rahimli, Laman, Meerten, Tom van, Cornely, Oliver A., Pagano, Livio, Doesum, Jaap van, Salmanton-García, Jon, Marchesi, Francesco, Blasi, Roberta di, Falces-Romero, Iker, Cabirta, Alba, Farina, Francesca, Besson, Caroline, Weinbergerová, Barbora, Praet, Jens van, Schönlein, Martin, López-García, Alberto, Lamure, Sylvain, Guidetti, Anna, Ramón, Cristina de, Batinić, Josip, Gavriilaki, Eleni, Tragiannidis, Athanasios, Tisi, Maria Chiara, Plantefeve, Gaëtan, Petzer, Verena, Ormazabal-Vélez, Irati, Marques de Almedia, Joyce, Marchetti, Monia, Maertens, Johan, Machado, Marina, Kulasekararaj, Austin G., Hernández-Rivas, José Ángel, Gomes Da Silva, María, Fernández, Noemí, Espigado, Ildefonso, Drgona, Lubos, Dragonetti, Giulia, Metafuni, Elisabetta, Calbacho, María, Blennow, Ola, Wolf, Dominik, Anrooij, Bjorn van, Nunes-Rodrigues, Raquel, Nordlander, Anna, Martín-González, Juan-Alberto, Lievin, Raphaël, Jiménez, Moraima, Gräfe, Stefanie, García-Sanz, Ramón, Córdoba, Raúl, Rahimli, Laman, Meerten, Tom van, Cornely, Oliver A., and Pagano, Livio
Abstract: Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19–caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.
Published: 2023

32. Molnupiravir Compared to Nirmatrelvir/Ritonavir for COVID-19 in High-Risk Patients with Haematological Malignancy in Europe. A Matched-Paired Analysis from the Epicovideha Registry

Author: Salmanton-Garcia, Jon, primary, Marchesi, Francesco, additional, Koehler, Philipp, additional, Weinbergerova, Barbora, additional, Čolovic, Natasa, additional, Falces-Romero, Iker, additional, Buquicchio, Caterina, additional, Farina, Francesca, additional, Van Praet, Jens, additional, Biernat, Monika M., additional, Itri, Federico, additional, Prezioso, Lucia, additional, Tascini, Carlo, additional, Vena, Antonio, additional, Romano, Alessandra, additional, Delia, Mario, additional, Davila-Valls, Julio, additional, Martín-Pérez, Sonia, additional, Lavilla-Rubira, Esperanza, additional, Adzic, Tatjana N., additional, Garcia-Bordado, Daniel, additional, Lopez-Garcia, Alberto, additional, Criscuolo, Mariana, additional, Petzer, Verena, additional, Fracchiolla, Nicola S., additional, Espigado, Ildefonso, additional, Sili, Uluhan, additional, Meers, Stef, additional, Erben, Nurettin, additional, Cattaneo, Chiara, additional, Tragiannidis, Athanasios, additional, Gavriilaki, Eleni, additional, Schönlein, Martin, additional, Mitrovic, Mirjana, additional, Pantic, Nikola, additional, Merelli, Maria, additional, Labrador, Jorge, additional, Hernández-Rivas, Jose Angel, additional, Glenthoj, Andreas, additional, Fouquet, Guillemette, additional, del Principe, Maria Ilaria, additional, Dargenio, Michelina, additional, Calbacho, Maria, additional, Besson, Caroline, additional, Kohn, Milena, additional, Grafe, Stefanie K., additional, Hersby, Ditte Stampe, additional, Arellano, Elena, additional, Çolak, Gökçe Melis, additional, Wolf, Dominik, additional, Marchetti, Monia, additional, Nordlander, Anna, additional, Blennow, Ola, additional, Cordoba, Raul, additional, Miskovic, Bojana, additional, Mladenovic, Miloš, additional, Bavastro, Martina, additional, LIMONGELLI, Alessandro, additional, Rahimli, Laman, additional, Pagano, Livio, additional, and Cornely, Oliver A., additional
Published: 2023
Full Text: View/download PDF

33. Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Author: Marchetti, Monia, primary, Salmanton-García, Jon, additional, El-Ashwah, Shaimaa, additional, Verga, Luisa, additional, Itri, Federico, additional, Ráčil, Zdeněk, additional, Dávila-Valls, Julio, additional, Martín-Pérez, Sonia, additional, Van Doesum, Jaap, additional, Passamonti, Francesco, additional, Abu-Zeinah, Ghaith, additional, Farina, Francesca, additional, López-García, Alberto, additional, Dragonetti, Giulia, additional, Cattaneo, Chiara, additional, Gomes Da Silva, Maria, additional, Bilgin, Yavuz M., additional, Žák, Pavel, additional, Petzer, Verena, additional, Glenthøj, Andreas, additional, Espigado, Ildefonso, additional, Buquicchio, Caterina, additional, Bonuomo, Valentina, additional, Prezioso, Lucia, additional, Meers, Stef, additional, Duarte, Rafael, additional, Bergantim, Rui, additional, Jaksic, Ozren, additional, Čolović, Natasha, additional, Blennow, Ola, additional, Cernan, Martin, additional, Schönlein, Martin, additional, Samarkos, Michail, additional, Mitra, Maria Enza, additional, Magliano, Gabriele, additional, Maertens, Johan, additional, Ledoux, Marie-Pierre, additional, Jiménez, Moraima, additional, Demirkan, Fatih, additional, Collins, Graham P., additional, Cabirta, Alba, additional, Gräfe, Stefanie K., additional, Nordlander, Anna, additional, Wolf, Dominik, additional, Arellano, Elena, additional, Cordoba, Raul, additional, Hanakova, Michaela, additional, Zambrotta, Giovanni Paolo Maria, additional, Nunes Rodrigues, Raquel, additional, Limberti, Giulia, additional, Marchesi, Francesco, additional, Cornely, Oliver A., additional, and Pagano, Livio, additional
Published: 2023
Full Text: View/download PDF

34. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Author: Pagano, Livio, primary, Salmanton-García, Jon, additional, Marchesi, Francesco, additional, Blennow, Ola, additional, Gomes da Silva, Maria, additional, Glenthøj, Andreas, additional, van Doesum, Jaap, additional, Bilgin, Yavuz M., additional, López-García, Alberto, additional, Itri, Federico, additional, Nunes Rodrigues, Raquel, additional, Weinbergerová, Barbora, additional, Farina, Francesca, additional, Dragonetti, Giulia, additional, Berg Venemyr, Caroline, additional, van Praet, Jens, additional, Jaksic, Ozren, additional, Valković, Toni, additional, Falces-Romero, Iker, additional, Martín-Pérez, Sonia, additional, Jiménez, Moraima, additional, Dávila-Valls, Julio, additional, Schönlein, Martin, additional, Ammatuna, Emanuele, additional, Meers, Stef, additional, Delia, Mario, additional, Stojanoski, Zlate, additional, Nordlander, Anna, additional, Lahmer, Tobias, additional, Imre Pinczés, László, additional, Buquicchio, Caterina, additional, Piukovics, Klára, additional, Ormazabal-Vélez, Irati, additional, Fracchiolla, Nicola, additional, Samarkos, Michail, additional, Méndez, Gustavo-Adolfo, additional, Hernández-Rivas, José-Ángel, additional, Espigado, Ildefonso, additional, Cernan, Martin, additional, Petzer, Verena, additional, Lamure, Sylvain, additional, di Blasi, Roberta, additional, Marques de Almedia, Joyce, additional, Dargenio, Michelina, additional, Biernat, Monika M., additional, Sciumè, Mariarita, additional, de Ramón, Cristina, additional, de Jonge, Nick, additional, Batinić, Josip, additional, Aujayeb, Avinash, additional, Marchetti, Monia, additional, Fouquet, Guillemette, additional, Fernández, Noemí, additional, Zambrotta, Giovanni, additional, Sacchi, Maria Vittoria, additional, Guidetti, Anna, additional, Demirkan, Fatih, additional, Prezioso, Lucia, additional, Ráčil, Zdeněk, additional, Nucci, Marcio, additional, Mladenović, Miloš, additional, Liévin, Raphaël, additional, Hanáková, Michaela, additional, Gräfe, Stefanie, additional, Sili, Uluhan, additional, Machado, Marina, additional, Cattaneo, Chiara, additional, Adžić-Vukičević, Tatjana, additional, Verga, Luisa, additional, Labrador, Jorge, additional, Rahimli, Laman, additional, Bonanni, Matteo, additional, Passamonti, Francesco, additional, Pagliuca, Antonio, additional, Corradini, Paolo, additional, Hoenigl, Martin, additional, Koehler, Philipp, additional, Busca, Alessandro, additional, and Cornely, Oliver A., additional
Published: 2022
Full Text: View/download PDF

35. 1591. The Impact of Pretransplant Respiratory Virus Infection in Pediatric Hematopoietic Cell Transplant Recipients

Author: Kim, Sara R, primary, Xie, Hu, additional, Kim, Yae-Jean, additional, Nordlander, Anna, additional, Ogimi, Chikara, additional, Leisenring, Wendy M, additional, Boeckh, Michael J, additional, Englund, Janet A, additional, and Waghmare, Alpana, additional
Published: 2022
Full Text: View/download PDF

36. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Author: Busca, Alessandro, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Seval, Guldane Cengiz, Van Doesum, Jaap, De Jonge, Nick, Bahr, Nathan C., Maertens, Johan, Meletiadis, Joseph, Fracchiolla, Nicola S., Weinbergerová, Barbora, Verga, Luisa, Ráčil, Zdeněk, Jiménez, Moraima, Glenthøj, Andreas, Blennow, Ola, Tanase, Alina Daniela, Schönlein, Martin, Prezioso, Lucia, Khanna, Nina, Duarte, Rafael F., Žák, Pavel, Nucci, Marcio, Machado, Marina, Kulasekararaj, Austin, Espigado, Ildefonso, De Kort, Elizabeth, Ribera-Santa Susana, José-María, Marchetti, Monia, Magliano, Gabriele, Falces-Romero, Iker, Ilhan, Osman, Ammatuna, Emanuele, Zompi, Sofia, Tsirigotis, Panagiotis, Antoniadou, Anastasia, Zambrotta, Giovanni Paolo Maria, Nordlander, Anna, Karlsson, Linda Katharina, Hanakova, Michaela, Dragonetti, Giulia, Cabirta, Alba, Berg Venemyr, Caroline, Gräfe, Stefanie, Van Praet, Jens, Tragiannidis, Athanasios, Petzer, Verena, López-García, Alberto, Itri, Federico, Groh, Ana, Gavriilaki, Eleni, Dargenio, Michelina, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, EPICOVIDEHA Consortium, [missing], Hematology, Institut Català de la Salut, [Busca A] Stem Cell Transplant Center, AOU Citta’ della Salute e della Scienza, Turin, Italy. [Salmanton-García J] University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany. [Marchesi F] Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Farina F] IRCCS Ospedale San Raffaele, Milan, Italy. [Seval GC] Ankara University, Ankara, Türkiye. [Van Doesum J] University Medical Center Groningen, Groningen, Netherlands. [Jiménez M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: hematological malignances, Cèl·lules mare hematopoètiques - Trasplantació, SARS-CoV-2, Hemic and Lymphatic Diseases::Hematologic Diseases [DISEASES], Immunology, allogeneic HSCT, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], COVID-19 (Malaltia), COVID-19 infection, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], enfermedades hematológicas y linfáticas::enfermedades hematológicas [ENFERMEDADES], Settore MED/15 - MALATTIE DEL SANGUE, All institutes and research themes of the Radboud University Medical Center, Allogeneic HSCT, Sang - Malalties, immunocompromised patients, Medicine and Health Sciences, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Hematological malignances, Immunocompromised patients, Immunology and Allergy, Therapeutics::Biological Therapy::Cell- and Tissue-Based Therapy::Cell Transplantation::Stem Cell Transplantation::Hematopoietic Stem Cell Transplantation [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], terapéutica::terapia biológica::tratamientos basados en células y tejidos::trasplante de células::trasplante de células madre::trasplante de células madre hematopoyéticas [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]
Abstract: COVID-19 infection; Hematological malignances; Immunocompromised patients Infecció per COVID-19; Neoplasies hematològiques; Pacients immunodeprimits Infección por COVID-19; Neoplasias hematológicas; Pacientes inmunodeprimidos Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection. EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223). The funder of the study had no role in study design, data analysis, interpretation, or writing of the report. All authors had full access to the data and had final responsibility for the decision to submit for publication.
Published: 2023

37. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Author: Cattaneo, Chiara, primary, Salmanton-García, Jon, additional, Marchesi, Francesco, additional, El-Ashwah, Shaimaa, additional, Itri, Federico, additional, Weinbergerová, Barbora, additional, Gomes Da Silva, Maria, additional, Dargenio, Michelina, additional, Dávila-Valls, Julio, additional, Martín-Pérez, Sonia, additional, Farina, Francesca, additional, Van Doesum, Jaap, additional, Valković, Toni, additional, Besson, Caroline, additional, Poulsen, Christian Bjørn, additional, López-García, Alberto, additional, Žák, Pavel, additional, Schönlein, Martin, additional, Piukovics, Klára, additional, Jaksic, Ozren, additional, Cabirta, Alba, additional, Ali, Natasha, additional, Sili, Uluhan, additional, Fracchiolla, Nicola, additional, Dragonetti, Giulia, additional, Adžić-Vukičević, Tatjana, additional, Marchetti, Monia, additional, Machado, Marina, additional, Glenthøj, Andreas, additional, Finizio, Olimpia, additional, Demirkan, Fatih, additional, Blennow, Ola, additional, Tisi, Maria Chiara, additional, Omrani, Ali S., additional, Navrátil, Milan, additional, Ráčil, Zdeněk, additional, Novák, Jan, additional, Magliano, Gabriele, additional, Jiménez, Moraima, additional, Garcia-Vidal, Carolina, additional, Erben, Nurettin, additional, Del Principe, Maria Ilaria, additional, Buquicchio, Caterina, additional, Bergantim, Rui, additional, Batinić, Josip, additional, Al-Khabori, Murtadha, additional, Verga, Luisa, additional, Szotkowski, Tomáš, additional, Samarkos, Michail, additional, Ormazabal-Vélez, Irati, additional, Meers, Stef, additional, Maertens, Johan, additional, Pinczés, László Imre, additional, Hoenigl, Martin, additional, Drgoňa, Ľuboš, additional, Cuccaro, Annarosa, additional, Bilgin, Yavuz M., additional, Aujayeb, Avinash, additional, Rahimli, Laman, additional, Gräfe, Stefanie, additional, Sciumè, Mariarita, additional, Mladenović, Miloš, additional, Çolak, Gökçe Melis, additional, Sacchi, Maria Vittoria, additional, Nordlander, Anna, additional, Berg Venemyr, Caroline, additional, Hanáková, Michaela, additional, García-Poutón, Nicole, additional, Emarah, Ziad, additional, Zambrotta, Giovanni Paolo Maria, additional, Nunes Rodrigues, Raquel, additional, Cordoba, Raul, additional, Méndez, Gustavo-Adolfo, additional, Biernat, Monika M., additional, Cornely, Oliver A., additional, and Pagano, Livio, additional
Published: 2022
Full Text: View/download PDF

38. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Author: Infante, Maria Stefania, primary, Salmanton-García, Jon, additional, Fernández-Cruz, Ana, additional, Marchesi, Francesco, additional, Jaksic, Ozren, additional, Weinbergerová, Barbora, additional, Besson, Caroline, additional, Duarte, Rafael F., additional, Itri, Federico, additional, Valković, Toni, additional, Szotkovski, Tomáš, additional, Busca, Alessandro, additional, Guidetti, Anna, additional, Glenthøj, Andreas, additional, Collins, Graham P., additional, Bonuomo, Valentina, additional, Sili, Uluhan, additional, Seval, Guldane Cengiz, additional, Machado, Marina, additional, Cordoba, Raul, additional, Blennow, Ola, additional, Abu-Zeinah, Ghaith, additional, Lamure, Sylvain, additional, Kulasekararaj, Austin, additional, Falces-Romero, Iker, additional, Cattaneo, Chiara, additional, Van Doesum, Jaap, additional, Piukovics, Klára, additional, Omrani, Ali S., additional, Magliano, Gabriele, additional, Ledoux, Marie-Pierre, additional, de Ramon, Cristina, additional, Cabirta, Alba, additional, Verga, Luisa, additional, López-García, Alberto, additional, Da Silva, Maria Gomes, additional, Stojanoski, Zlate, additional, Meers, Stef, additional, Lahmer, Tobias, additional, Martín-Pérez, Sonia, additional, Dávila-Vals, Julio, additional, Van Praet, Jens, additional, Samarkos, Michail, additional, Bilgin, Yavuz M., additional, Karlsson, Linda Katharina, additional, Batinić, Josip, additional, Nordlander, Anna, additional, Schönlein, Martin, additional, Hoenigl, Martin, additional, Ráčil, Zdeněk, additional, Mladenović, Miloš, additional, Hanakova, Michaela, additional, Zambrotta, Giovanni Paolo Maria, additional, De Jonge, Nick, additional, Adžić-Vukičević, Tatjana, additional, Nunes-Rodrigues, Raquel, additional, Prezioso, Lucia, additional, Navrátil, Milan, additional, Marchetti, Monia, additional, Cuccaro, Annarosa, additional, Calbacho, Maria, additional, Giordano, Antonio, additional, Cornely, Oliver A., additional, Hernández-Rivas, José-Ángel, additional, and Pagano, Livio, additional
Published: 2022
Full Text: View/download PDF

39. COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

Author: Lamure, Sylvain, primary, Salmanton-García, Jon, additional, Robin-Marieton, Elena, additional, Jaksic, Ozren, additional, Kohn, Milena, additional, Marchesi, Francesco, additional, Marchetti, Monia, additional, El-Ashwah, Shaimaa, additional, Demirkan, Fatih, additional, Valković, Toni, additional, Fernández, Noemí, additional, Tisi, Maria Chiara, additional, Stojanoski, Zlate, additional, Seval, Guldane Cengiz, additional, Ilhan, Osman, additional, Prezioso, Lucia, additional, Merelli, Maria, additional, López-García, Alberto, additional, Ledoux, Marie-Pierre, additional, Kulasekararaj, Austin, additional, González-López, Tomás-José, additional, Gomes da Silva, Maria, additional, Emarah, Ziad, additional, Duarte, Rafael F., additional, Cattaneo, Chiara, additional, Blennow, Ola, additional, Bilgin, Yavuz M., additional, Bergantim, Rui, additional, Batinić, Josip, additional, Cordoba, Raul, additional, Essame, Jenna, additional, Nordlander, Anna, additional, Nunes Rodrigues, Raquel, additional, Sacchi, Maria Vittoria, additional, Zompi, Sofia, additional, Busca, Alessandro, additional, Corradini, Paolo, additional, Hoenigl, Martin, additional, Klimko, Nikolai, additional, Koehler, Philipp, additional, Pagliuca, Antonio, additional, Passamonti, Francesco, additional, Duléry, Rémy, additional, Cornely, Oliver A., additional, Besson, Caroline, additional, and Pagano, Livio, additional
Published: 2022
Full Text: View/download PDF

40. Outcome of infection with omicron SARS‐CoV ‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Author: Blennow, Ola, primary, Salmanton‐García, Jon, additional, Nowak, Piotr, additional, Itri, Federico, additional, Van Doesum, Jaap, additional, López‐García, Alberto, additional, Farina, Francesca, additional, Jaksic, Ozren, additional, Pinczés, László Imre, additional, Bilgin, Yavuz M., additional, Falces‐Romero, Iker, additional, Jiménez, Moraima, additional, Ormazabal‐Vélez, Irati, additional, Weinbergerová, Barbora, additional, Duléry, Rémy, additional, Stojanoski, Zlate, additional, Lahmer, Tobias, additional, Fernández, Noemí, additional, Hernández‐Rivas, José‐Ángel, additional, Petzer, Verena, additional, De Jonge, Nick, additional, Glenthøj, Andreas, additional, De Ramón, Cristina, additional, Biernat, Monika M., additional, Fracchiolla, Nicola, additional, Aujayeb, Avinash, additional, Van Praet, Jens, additional, Schönlein, Martin, additional, Méndez, Gustavo‐Adolfo, additional, Cattaneo, Chiara, additional, Guidetti, Anna, additional, Sciumè, Mariarita, additional, Ammatuna, Emanuele, additional, Cordoba, Raul, additional, García‐Poutón, Nicole, additional, Gräfe, Stefanie, additional, Cabirta, Alba, additional, Wolf, Dominik, additional, Nordlander, Anna, additional, García‐Sanz, Ramón, additional, Delia, Mario, additional, Berg Venemyr, Caroline, additional, Brones, Clara, additional, Di Blasi, Roberta, additional, De Kort, Elizabeth, additional, Meers, Stef, additional, Lamure, Sylvain, additional, Serrano, Laura, additional, Merelli, Maria, additional, Coppola, Nicola, additional, Bergantim, Rui, additional, Besson, Caroline, additional, Kohn, Milena, additional, Petiti, Jessica, additional, Garcia‐Vidal, Carolina, additional, Dargenio, Michelina, additional, Danion, François, additional, Machado, Marina, additional, Bailén‐Almorox, Rebeca, additional, Hoenigl, Martin, additional, Dragonetti, Giulia, additional, Chai, Louis Yi Ann, additional, Kho, Chi Shan, additional, Bonanni, Matteo, additional, Liévin, Raphaël, additional, Marchesi, Francesco, additional, Cornely, Oliver A., additional, and Pagano, Livio, additional
Published: 2022
Full Text: View/download PDF

41. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP.

Author: Busca, Alessandro, Busca, Alessandro, Salmanton-García, Jon, Corradini, Paolo, Marchesi, Francesco, Cabirta, Alba, Di Blasi, Roberta, Dulery, Remy, Lamure, Sylvain, Farina, Francesca, Weinbergerová, Barbora, Batinić, Josip, Nordlander, Anna, López-García, Alberto, Drgoňa, Ľuboš, Espigado-Tocino, Ildefonso, Falces-Romero, Iker, García-Sanz, Ramón, García-Vidal, Carolina, Guidetti, Anna, Khanna, Nina, Kulasekararaj, Austin, Maertens, Johan, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A, Pagano, Livio, Busca, Alessandro, Busca, Alessandro, Salmanton-García, Jon, Corradini, Paolo, Marchesi, Francesco, Cabirta, Alba, Di Blasi, Roberta, Dulery, Remy, Lamure, Sylvain, Farina, Francesca, Weinbergerová, Barbora, Batinić, Josip, Nordlander, Anna, López-García, Alberto, Drgoňa, Ľuboš, Espigado-Tocino, Ildefonso, Falces-Romero, Iker, García-Sanz, Ramón, García-Vidal, Carolina, Guidetti, Anna, Khanna, Nina, Kulasekararaj, Austin, Maertens, Johan, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A, and Pagano, Livio
Abstract: The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
Published: 2022

42. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.

Author: Pagano, Livio, Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Blennow, Ola, Gomes da Silva, Maria, Glenthøj, Andreas, van Doesum, Jaap, Bilgin, Yavuz M, López-García, Alberto, Itri, Federico, Nunes Rodrigues, Raquel, Weinbergerová, Barbora, Farina, Francesca, Dragonetti, Giulia, Berg Venemyr, Caroline, van Praet, Jens, Jaksic, Ozren, Valković, Toni, Falces-Romero, Iker, Martín-Pérez, Sonia, Jiménez, Moraima, Dávila-Valls, Julio, Schönlein, Martin, Ammatuna, Emanuele, Meers, Stef, Delia, Mario, Stojanoski, Zlate, Nordlander, Anna, Lahmer, Tobias, Imre Pinczés, László, Buquicchio, Caterina, Piukovics, Klára, Ormazabal-Vélez, Irati, Fracchiolla, Nicola, Samarkos, Michail, Méndez, Gustavo-Adolfo, Hernández-Rivas, José-Ángel, Espigado, Ildefonso, Cernan, Martin, Petzer, Verena, Lamure, Sylvain, di Blasi, Roberta, Marques de Almedia, Joyce, Dargenio, Michelina, Biernat, Monika M, Sciumè, Mariarita, de Ramón, Cristina, de Jonge, Nick, Batinić, Josip, Aujayeb, Avinash, Marchetti, Monia, Fouquet, Guillemette, Fernández, Noemí, Zambrotta, Giovanni, Sacchi, Maria Vittoria, Guidetti, Anna, Demirkan, Fatih, Prezioso, Lucia, Ráčil, Zdeněk, Nucci, Marcio, Mladenović, Miloš, Liévin, Raphaël, Hanáková, Michaela, Gräfe, Stefanie, Sili, Uluhan, Machado, Marina, Cattaneo, Chiara, Adžić-Vukičević, Tatjana, Verga, Luisa, Labrador, Jorge, Rahimli, Laman, Bonanni, Matteo, Passamonti, Francesco, Pagliuca, Antonio, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Busca, Alessandro, Cornely, Oliver A, Pagano, Livio, Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Blennow, Ola, Gomes da Silva, Maria, Glenthøj, Andreas, van Doesum, Jaap, Bilgin, Yavuz M, López-García, Alberto, Itri, Federico, Nunes Rodrigues, Raquel, Weinbergerová, Barbora, Farina, Francesca, Dragonetti, Giulia, Berg Venemyr, Caroline, van Praet, Jens, Jaksic, Ozren, Valković, Toni, Falces-Romero, Iker, Martín-Pérez, Sonia, Jiménez, Moraima, Dávila-Valls, Julio, Schönlein, Martin, Ammatuna, Emanuele, Meers, Stef, Delia, Mario, Stojanoski, Zlate, Nordlander, Anna, Lahmer, Tobias, Imre Pinczés, László, Buquicchio, Caterina, Piukovics, Klára, Ormazabal-Vélez, Irati, Fracchiolla, Nicola, Samarkos, Michail, Méndez, Gustavo-Adolfo, Hernández-Rivas, José-Ángel, Espigado, Ildefonso, Cernan, Martin, Petzer, Verena, Lamure, Sylvain, di Blasi, Roberta, Marques de Almedia, Joyce, Dargenio, Michelina, Biernat, Monika M, Sciumè, Mariarita, de Ramón, Cristina, de Jonge, Nick, Batinić, Josip, Aujayeb, Avinash, Marchetti, Monia, Fouquet, Guillemette, Fernández, Noemí, Zambrotta, Giovanni, Sacchi, Maria Vittoria, Guidetti, Anna, Demirkan, Fatih, Prezioso, Lucia, Ráčil, Zdeněk, Nucci, Marcio, Mladenović, Miloš, Liévin, Raphaël, Hanáková, Michaela, Gräfe, Stefanie, Sili, Uluhan, Machado, Marina, Cattaneo, Chiara, Adžić-Vukičević, Tatjana, Verga, Luisa, Labrador, Jorge, Rahimli, Laman, Bonanni, Matteo, Passamonti, Francesco, Pagliuca, Antonio, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Busca, Alessandro, and Cornely, Oliver A
Abstract: Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received ≤2 vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P < .001), active HM (P < .001), and severe and critical COVID-19 (P = .007 and P < .001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P < .001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P < .001) or combined with antivirals (P = .009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.
Published: 2022

43. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Author: Cattaneo, Chiara, Salmanton-Garcia, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Itri, Federico, Weinbergerova, Barbora, Da Silva, Maria Gomes, Dargenio, Michelina, Davila-Valls, Julio, Martin-Perez, Sonia, Farina, Francesca, Van Doesum, Jaap, Valkovic, Toni, Besson, Caroline, Poulsen, Christian Bjorn, Lopez-Garcia, Alberto, Zak, Pavel, Schonlein, Martin, Piukovics, Klara, Jaksic, Ozren, Cabirta, Alba, Ali, Natasha, Sili, Uluhan, Fracchiolla, Nicola, Dragonetti, Giulia, Adzic-Vukicevic, Tatjana, Marchetti, Monia, Machado, Marina, Glenthoj, Andreas, Finizio, Olimpia, Demirkan, Fatih, Blennow, Ola, Tisi, Maria Chiara, Omrani, Ali S., Navratil, Milan, Racil, Zdenek, Novak, Jan, Magliano, Gabriele, Jimenez, Moraima, Garcia-Vidal, Carolina, Erben, Nurettin, Del Principe, Maria Ilaria, Buquicchio, Caterina, Bergantim, Rui, Batinic, Josip, Al-Khabori, Murtadha, Verga, Luisa, Szotkowski, Tomas, Samarkos, Michail, Ormazabal-Velez, Irati, Meers, Stef, Maertens, Johan, Pinczes, Laszlo Imre, Hoenigl, Martin, Drgona, L'ubos, Cuccaro, Annarosa, Bilgin, Yavuz M., Aujayeb, Avinash, Rahimli, Laman, Grafe, Stefanie, Sciume, Mariarita, Mladenovic, Milos, Colak, Gokce Melis, Sacchi, Maria Vittoria, Nordlander, Anna, Venemyr, Caroline Berg, Hanakova, Michaela, Garcia-Pouton, Nicole, Emarah, Ziad, Zambrotta, Giovanni Paolo Maria, Rodrigues, Raquel Nunes, Cordoba, Raul, Mendez, Gustavo-Adolfo, Biernat, Monika M., Cornely, Oliver A., Pagano, Livio, Cattaneo, Chiara, Salmanton-Garcia, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Itri, Federico, Weinbergerova, Barbora, Da Silva, Maria Gomes, Dargenio, Michelina, Davila-Valls, Julio, Martin-Perez, Sonia, Farina, Francesca, Van Doesum, Jaap, Valkovic, Toni, Besson, Caroline, Poulsen, Christian Bjorn, Lopez-Garcia, Alberto, Zak, Pavel, Schonlein, Martin, Piukovics, Klara, Jaksic, Ozren, Cabirta, Alba, Ali, Natasha, Sili, Uluhan, Fracchiolla, Nicola, Dragonetti, Giulia, Adzic-Vukicevic, Tatjana, Marchetti, Monia, Machado, Marina, Glenthoj, Andreas, Finizio, Olimpia, Demirkan, Fatih, Blennow, Ola, Tisi, Maria Chiara, Omrani, Ali S., Navratil, Milan, Racil, Zdenek, Novak, Jan, Magliano, Gabriele, Jimenez, Moraima, Garcia-Vidal, Carolina, Erben, Nurettin, Del Principe, Maria Ilaria, Buquicchio, Caterina, Bergantim, Rui, Batinic, Josip, Al-Khabori, Murtadha, Verga, Luisa, Szotkowski, Tomas, Samarkos, Michail, Ormazabal-Velez, Irati, Meers, Stef, Maertens, Johan, Pinczes, Laszlo Imre, Hoenigl, Martin, Drgona, L'ubos, Cuccaro, Annarosa, Bilgin, Yavuz M., Aujayeb, Avinash, Rahimli, Laman, Grafe, Stefanie, Sciume, Mariarita, Mladenovic, Milos, Colak, Gokce Melis, Sacchi, Maria Vittoria, Nordlander, Anna, Venemyr, Caroline Berg, Hanakova, Michaela, Garcia-Pouton, Nicole, Emarah, Ziad, Zambrotta, Giovanni Paolo Maria, Rodrigues, Raquel Nunes, Cordoba, Raul, Mendez, Gustavo-Adolfo, Biernat, Monika M., Cornely, Oliver A., and Pagano, Livio
Abstract: Simple Summary Patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 are an even greater challenge for hematologists. To better clarify their outcome, we describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Overall, 343 (76.2%) patients received treatment for HM, and an overall response rate was observed in 140 (40.8%) patients after the first line of treatment. Thirty-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004). Statistical analysis showed that, together with age, severe/critical COVID-19, >= 2 comorbidities, lack of HM treatment was an independent risk factors for mortality. These observations suggest the importance of HM treatment in these patients; therefore, it should be delivered as soon as possible for patients requiring immediate therapy. Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to
Published: 2022

44. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Author: Infante, Maria Stefania, Salmanton-Garcia, Jon, Fernandez-Cruz, Ana, Marchesi, Francesco, Jaksic, Ozren, Weinbergerova, Barbora, Besson, Caroline, Duarte, Rafael F., Itri, Federico, Valkovic, Toni, Szotkovski, Tomas, Busca, Alessandro, Guidetti, Anna, Glenthoj, Andreas, Collins, Graham P., Bonuomo, Valentina, Sili, Uluhan, Seval, Guldane Cengiz, Machado, Marina, Cordoba, Raul, Blennow, Ola, Abu-Zeinah, Ghaith, Lamure, Sylvain, Kulasekararaj, Austin, Falces-Romero, Iker, Cattaneo, Chiara, Van Doesum, Jaap, Piukovics, Klara, Omrani, Ali S., Magliano, Gabriele, Ledoux, Marie-Pierre, de Ramon, Cristina, Cabirta, Alba, Verga, Luisa, Lopez-Garcia, Alberto, Da Silva, Maria Gomes, Stojanoski, Zlate, Meers, Stef, Lahmer, Tobias, Martin-Perez, Sonia, Davila-Vals, Julio, Van Praet, Jens, Samarkos, Michail, Bilgin, Yavuz M., Karlsson, Linda Katharina, Batinic, Josip, Nordlander, Anna, Schonlein, Martin, Hoenigl, Martin, Racil, Zdenek, Mladenovic, Milos, Hanakova, Michaela, Zambrotta, Giovanni Paolo Maria, De Jonge, Nick, Adzic-Vukicevic, Tatjana, Nunes-Rodrigues, Raquel, Prezioso, Lucia, Navratil, Milan, Marchetti, Monia, Cuccaro, Annarosa, Calbacho, Maria, Giordano, Antonio, Cornely, Oliver A., Hernandez-Rivas, Jose-Angel, Pagano, Livio, Infante, Maria Stefania, Salmanton-Garcia, Jon, Fernandez-Cruz, Ana, Marchesi, Francesco, Jaksic, Ozren, Weinbergerova, Barbora, Besson, Caroline, Duarte, Rafael F., Itri, Federico, Valkovic, Toni, Szotkovski, Tomas, Busca, Alessandro, Guidetti, Anna, Glenthoj, Andreas, Collins, Graham P., Bonuomo, Valentina, Sili, Uluhan, Seval, Guldane Cengiz, Machado, Marina, Cordoba, Raul, Blennow, Ola, Abu-Zeinah, Ghaith, Lamure, Sylvain, Kulasekararaj, Austin, Falces-Romero, Iker, Cattaneo, Chiara, Van Doesum, Jaap, Piukovics, Klara, Omrani, Ali S., Magliano, Gabriele, Ledoux, Marie-Pierre, de Ramon, Cristina, Cabirta, Alba, Verga, Luisa, Lopez-Garcia, Alberto, Da Silva, Maria Gomes, Stojanoski, Zlate, Meers, Stef, Lahmer, Tobias, Martin-Perez, Sonia, Davila-Vals, Julio, Van Praet, Jens, Samarkos, Michail, Bilgin, Yavuz M., Karlsson, Linda Katharina, Batinic, Josip, Nordlander, Anna, Schonlein, Martin, Hoenigl, Martin, Racil, Zdenek, Mladenovic, Milos, Hanakova, Michaela, Zambrotta, Giovanni Paolo Maria, De Jonge, Nick, Adzic-Vukicevic, Tatjana, Nunes-Rodrigues, Raquel, Prezioso, Lucia, Navratil, Milan, Marchetti, Monia, Cuccaro, Annarosa, Calbacho, Maria, Giordano, Antonio, Cornely, Oliver A., Hernandez-Rivas, Jose-Angel, and Pagano, Livio
Abstract: Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
Published: 2022

45. COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

Author: Lamure, Sylvain, Salmanton-Garcia, Jon, Robin-Marieton, Elena, Jaksic, Ozren, Kohn, Milena, Marchesi, Francesco, Marchetti, Monia, El-Ashwah, Shaimaa, Demirkan, Faith, Valkovic, Toni, Fernandez, Noemi, Tisi, Maria Chiara, Stojanoski, Zlate, Seval, Guldane Cengiz, Ilhan, Osman, Prezioso, Lucia, Merelli, Maria, Lopez-Garcia, Alberto, Ledoux, Marie-Pierre, Kulasekararaj, Austin, Gonzalez-Lopez, Tomas-Jose, da Silva, Maria Gomes, Emarah, Ziad, Duarte, Rafael F., Cattaneo, Chiara, Blennow, Ola, Bilgin, Yavuz M., Bergantim, Rui, Batinic, Josip, Cordoba, Raul, Essame, Jenna, Nordlander, Anna, Rodrigues, Raquel Nunes, Sacchi, Maria Vittoria, Zompi, Sofia, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Dulery, Remy, Cornely, Oliver A., Besson, Caroline, Pagano, Livio, Lamure, Sylvain, Salmanton-Garcia, Jon, Robin-Marieton, Elena, Jaksic, Ozren, Kohn, Milena, Marchesi, Francesco, Marchetti, Monia, El-Ashwah, Shaimaa, Demirkan, Faith, Valkovic, Toni, Fernandez, Noemi, Tisi, Maria Chiara, Stojanoski, Zlate, Seval, Guldane Cengiz, Ilhan, Osman, Prezioso, Lucia, Merelli, Maria, Lopez-Garcia, Alberto, Ledoux, Marie-Pierre, Kulasekararaj, Austin, Gonzalez-Lopez, Tomas-Jose, da Silva, Maria Gomes, Emarah, Ziad, Duarte, Rafael F., Cattaneo, Chiara, Blennow, Ola, Bilgin, Yavuz M., Bergantim, Rui, Batinic, Josip, Cordoba, Raul, Essame, Jenna, Nordlander, Anna, Rodrigues, Raquel Nunes, Sacchi, Maria Vittoria, Zompi, Sofia, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Dulery, Remy, Cornely, Oliver A., Besson, Caroline, and Pagano, Livio
Published: 2022

46. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Author: Blennow, Ola, Salmanton-Garcia, Jon, Nowak, Piotr, Itri, Federico, Van Doesum, Jaap, Lopez-Garcia, Alberto, Farina, Francesca, Jaksic, Ozren, Pinczes, Laszlo Imre, Bilgin, Yavuz M., Falces-Romero, Iker, Jimenez, Moraima, Ormazabal-Velez, Irati, Weinbergerova, Barbora, Dulery, Remy, Stojanoski, Zlate, Lahmer, Tobias, Fernandez, Noemi, Hernandez-Rivas, Jose-angel, Petzer, Verena, De Jonge, Nick, Glenthoj, Andreas, De Ramon, Cristina, Biernat, Monika M., Fracchiolla, Nicola, Aujayeb, Avinash, Van Praet, Jens, Schonlein, Martin, Mendez, Gustavo-Adolfo, Cattaneo, Chiara, Guidetti, Anna, Sciume, Mariarita, Ammatuna, Emanuele, Cordoba, Raul, Garcia-Pouton, Nicole, Graefe, Stefanie, Cabirta, Alba, Wolf, Dominik, Nordlander, Anna, Garcia-Sanz, Ramon, Delia, Mario, Berg Venemyr, Caroline, Brones, Clara, Di Blasi, Roberta, De Kort, Elizabeth, Meers, Stef, Lamure, Sylvain, Serrano, Laura, Merelli, Maria, Coppola, Nicola, Bergantim, Rui, Besson, Caroline, Kohn, Milena, Petiti, Jessica, Garcia-Vidal, Carolina, Dargenio, Michelina, Danion, Francois, Machado, Marina, Bailen-Almorox, Rebeca, Hoenigl, Martin, Dragonetti, Giulia, Chai, Louis Yi Ann, Kho, Chi Shan, Bonanni, Matteo, Lievin, Raphael, Marchesi, Francesco, Cornely, Oliver A., Pagano, Livio, Blennow, Ola, Salmanton-Garcia, Jon, Nowak, Piotr, Itri, Federico, Van Doesum, Jaap, Lopez-Garcia, Alberto, Farina, Francesca, Jaksic, Ozren, Pinczes, Laszlo Imre, Bilgin, Yavuz M., Falces-Romero, Iker, Jimenez, Moraima, Ormazabal-Velez, Irati, Weinbergerova, Barbora, Dulery, Remy, Stojanoski, Zlate, Lahmer, Tobias, Fernandez, Noemi, Hernandez-Rivas, Jose-angel, Petzer, Verena, De Jonge, Nick, Glenthoj, Andreas, De Ramon, Cristina, Biernat, Monika M., Fracchiolla, Nicola, Aujayeb, Avinash, Van Praet, Jens, Schonlein, Martin, Mendez, Gustavo-Adolfo, Cattaneo, Chiara, Guidetti, Anna, Sciume, Mariarita, Ammatuna, Emanuele, Cordoba, Raul, Garcia-Pouton, Nicole, Graefe, Stefanie, Cabirta, Alba, Wolf, Dominik, Nordlander, Anna, Garcia-Sanz, Ramon, Delia, Mario, Berg Venemyr, Caroline, Brones, Clara, Di Blasi, Roberta, De Kort, Elizabeth, Meers, Stef, Lamure, Sylvain, Serrano, Laura, Merelli, Maria, Coppola, Nicola, Bergantim, Rui, Besson, Caroline, Kohn, Milena, Petiti, Jessica, Garcia-Vidal, Carolina, Dargenio, Michelina, Danion, Francois, Machado, Marina, Bailen-Almorox, Rebeca, Hoenigl, Martin, Dragonetti, Giulia, Chai, Louis Yi Ann, Kho, Chi Shan, Bonanni, Matteo, Lievin, Raphael, Marchesi, Francesco, Cornely, Oliver A., and Pagano, Livio
Published: 2022

47. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Author: Gilead Sciences, Blennow, Ola, Salmanton-García, Jon, Nowak, Piotr, Itri, Federico, Doesum, Jaap van, López-García, Alberto, Farina, Francesca, Jakšić, Ozren, Pinczés, László Imre, Bilgin, Yavuz M., Falces-Romero, Iker, Jiménez, Moraima, Ormazabal-Vélez, Irati, Weinbergerová, Barbora, Duléry, Rémy, Stojanoski, Zlate, Lahmer, Tobias, Fernández, Noemí, Hernández-Rivas, José Ángel, Petzer, Verena, Jonge, Nick de, Glenthøj, Andrea, Ramón, Cristina de, Biernat, Monika, Fracchiolla, Nicola S., Aujayeb, Avinash, Praet, Jens van, Schönlein, Martin, Méndez, Gustavo-Adolfo, Cattaneo, Chiara, Guidetti, Anna, Sciumè, Mariarita, Ammatuna, Emanuele, Córdoba, Raúl, García-Poutón, Nicole, Gräfe, Stefanie, Cabirta, Alba, Wolf, Dominik, Nordlander, Anna, García-Sanz, Ramón, Delia, Mario, Berg Venemyr, Caroline, Brones, Clara, Di Blasi, Roberta, Kort, Elizabeth De, Meers, Stef, Lamure, Sylvain, Serrano, Laura, Merelli, Maria, Coppola, Nicola, Bergantim, Rui, Besson, Caroline, Kohn, Milena, Petiti, Jessica, García-Vidal, Carolina, Dargenio, Michelina, Danion, François, Machado, Marina, Bailén-Almorox, Rebeca, Hoenigl, Martin, Dragonetti, Giulia, Yi Ann Chai, Louis, Shan Kho, Chi, Bonanni, Matteo, Lievin, Raphaël, Marchesi, Francesco, Cornely, Oliver A., Pagano, Livio, Gilead Sciences, Blennow, Ola, Salmanton-García, Jon, Nowak, Piotr, Itri, Federico, Doesum, Jaap van, López-García, Alberto, Farina, Francesca, Jakšić, Ozren, Pinczés, László Imre, Bilgin, Yavuz M., Falces-Romero, Iker, Jiménez, Moraima, Ormazabal-Vélez, Irati, Weinbergerová, Barbora, Duléry, Rémy, Stojanoski, Zlate, Lahmer, Tobias, Fernández, Noemí, Hernández-Rivas, José Ángel, Petzer, Verena, Jonge, Nick de, Glenthøj, Andrea, Ramón, Cristina de, Biernat, Monika, Fracchiolla, Nicola S., Aujayeb, Avinash, Praet, Jens van, Schönlein, Martin, Méndez, Gustavo-Adolfo, Cattaneo, Chiara, Guidetti, Anna, Sciumè, Mariarita, Ammatuna, Emanuele, Córdoba, Raúl, García-Poutón, Nicole, Gräfe, Stefanie, Cabirta, Alba, Wolf, Dominik, Nordlander, Anna, García-Sanz, Ramón, Delia, Mario, Berg Venemyr, Caroline, Brones, Clara, Di Blasi, Roberta, Kort, Elizabeth De, Meers, Stef, Lamure, Sylvain, Serrano, Laura, Merelli, Maria, Coppola, Nicola, Bergantim, Rui, Besson, Caroline, Kohn, Milena, Petiti, Jessica, García-Vidal, Carolina, Dargenio, Michelina, Danion, François, Machado, Marina, Bailén-Almorox, Rebeca, Hoenigl, Martin, Dragonetti, Giulia, Yi Ann Chai, Louis, Shan Kho, Chi, Bonanni, Matteo, Lievin, Raphaël, Marchesi, Francesco, Cornely, Oliver A., and Pagano, Livio
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused high mortality in patients with hematological malignancies (HM).1 The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutations that raise concerns about vaccine efficiency and antiviral efficacy of the available therapeutic monoclonal antibodies.2 The first published clinical data in immunocompetent patients have found that infection with omicron variants is associated with reduced vaccine efficiency compared to the delta variants, but decreased hospital admission and mortality.3, 4 Preliminary, prepublished, data from a large case–control study have shown that the vaccine effect against omicron in immunocompromised patients, including HM patients, is even more reduced, but data regarding clinical outcomes are lacking.5 The aim of this study was to describe risk factors, antiviral treatment and outcomes of SARS-CoV-2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry.
Published: 2022

48. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Author: Gilead Sciences, Infante, María-Stefania, Salmanton-García, Jon, Ana Fernández-Cruz, Marchesi, Francesco, Jakšić, Ozren, Weinbergerová, Barbora, Duarte, Rafael F., Itri, Federico, Valković, Toni, Szotkovski, Tomas, Busca, Alessandro, Guidetti, Anna, Glenthøj, Andrea, Collins, Graham P., Bonuomo, Valentina, Sili, Uluhan, Cengiz Seval, Guldane, Machado, Marina, Córdoba, Raúl, Blennow, Ola, Abu-Zeinah, Ghaith, Lamure, Sylvain, Kulasekararaj, Austin G., Falces-Romero, Iker, Cattaneo, Chiara, Doesum, Jaap van, Piukovics, Klára, Omrani, Ali S., Magliano, Gabriel, Ledoux, Marie-Pierre, Ramón, Cristina de, Cabirta, Alba, Verga, Luisa, López-García, Alberto, Gomes Da Silva, María, Stojanoski, Zlate, Meers, Stef, Lahmer, Tobias, Martín-Pérez, Sonia, Dávila, Julio, Praet, Jens van, Samarkos, Michail, Bilgin, Yavuz M., Karlsson, Linda Katharina, Batinić, Josip, Nordlander, Anna, Schönlein, Martin, Hoenigl, Martin, Ráčil, Zdeněk, Mladenovic, Milos, Hanakova, Michaela, Zambrotta, Giovanni, Jonge, Nick de, Adžić-Vukičević, Tatjana, Nunes-Rodrigues, Raquel, Prezioso, Lucia, Navrátil, Milan, Marchetti, Monia, Cuccaro, Annarosa, Calbacho, María, Giordano, Antonio, Cornely, Oliver A., Hernández-Rivas, José Ángel, Pagano, Livio, Gilead Sciences, Infante, María-Stefania, Salmanton-García, Jon, Ana Fernández-Cruz, Marchesi, Francesco, Jakšić, Ozren, Weinbergerová, Barbora, Duarte, Rafael F., Itri, Federico, Valković, Toni, Szotkovski, Tomas, Busca, Alessandro, Guidetti, Anna, Glenthøj, Andrea, Collins, Graham P., Bonuomo, Valentina, Sili, Uluhan, Cengiz Seval, Guldane, Machado, Marina, Córdoba, Raúl, Blennow, Ola, Abu-Zeinah, Ghaith, Lamure, Sylvain, Kulasekararaj, Austin G., Falces-Romero, Iker, Cattaneo, Chiara, Doesum, Jaap van, Piukovics, Klára, Omrani, Ali S., Magliano, Gabriel, Ledoux, Marie-Pierre, Ramón, Cristina de, Cabirta, Alba, Verga, Luisa, López-García, Alberto, Gomes Da Silva, María, Stojanoski, Zlate, Meers, Stef, Lahmer, Tobias, Martín-Pérez, Sonia, Dávila, Julio, Praet, Jens van, Samarkos, Michail, Bilgin, Yavuz M., Karlsson, Linda Katharina, Batinić, Josip, Nordlander, Anna, Schönlein, Martin, Hoenigl, Martin, Ráčil, Zdeněk, Mladenovic, Milos, Hanakova, Michaela, Zambrotta, Giovanni, Jonge, Nick de, Adžić-Vukičević, Tatjana, Nunes-Rodrigues, Raquel, Prezioso, Lucia, Navrátil, Milan, Marchetti, Monia, Cuccaro, Annarosa, Calbacho, María, Giordano, Antonio, Cornely, Oliver A., Hernández-Rivas, José Ángel, and Pagano, Livio
Abstract: Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
Published: 2022

49. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Author: Gilead Sciences, Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Blennow, Ola, Gomes Da Silva, María, Glenthøj, Andrea, Doesum, Jaap van, Bilgin, Yavuz M., López-García, Alberto, Itri, Federico, Nunes-Rodrigues, Raquel, Farina, Francesca, Dragonetti, Giulia, Berg Venemyr, Caroline, Praet, Jens van, Jakšić, Ozren, Valković, Toni, Falces-Romero, Iker, Martín-Pérez, Sonia, Jiménez, Moraima, Dávila, Julio, Schönlein, Martin, Ammatuna, Emanuele, Meers, Stef, Delia, Mario, Stojanoski, Zlate, Nordlander, Anna, Lahmer, Tobias, Pinczés, László Imre, Buquicchio, Caterina, Piukovics, Klára, Ormazabal-Vélez, Irati, Fracchiolla, Nicola S., Samarkos, Michail, Méndez, Gustavo-Adolfo, Hernández-Rivas, José Ángel, Espigado, Ildefonso, Čerňan, Martin, Petzer, Verena, Lamure, Sylvain, Blasi, Roberta di, Marques de Almedia, Joyce, Dargenio, Michelina, Biernat, Monika, Sciumè, Mariarita, Ramón, Cristina de, Jonge, Nick de, Batinić, Josip, Aujayeb, Avinash, Marchetti, Monia, Fouquet, Guillemette, Fernández, Noemí, Zambrotta, Giovanni, Sacchi, Maria Vittoria, Guidetti, Anna, Demirkan, Fatih, Prezioso, Lucia, Ráčil, Zdeněk, Nucci, Marcio, Mladenovic, Milos, Lievin, Raphaël, Hanakova, Michaela, Gräfe, Stefanie, Sili, Uluhan, Machado, Marina, Cattaneo, Chiara, Adžić-Vukičević, Tatjana, Verga, Luisa, Labrador, Jorge, Rahimli, Laman, Bonanni, Matteo, Passamonti, Francesco, Pagliuca, Antonio, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Busca, Alessandro, Cornely, Oliver A., Gilead Sciences, Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Blennow, Ola, Gomes Da Silva, María, Glenthøj, Andrea, Doesum, Jaap van, Bilgin, Yavuz M., López-García, Alberto, Itri, Federico, Nunes-Rodrigues, Raquel, Farina, Francesca, Dragonetti, Giulia, Berg Venemyr, Caroline, Praet, Jens van, Jakšić, Ozren, Valković, Toni, Falces-Romero, Iker, Martín-Pérez, Sonia, Jiménez, Moraima, Dávila, Julio, Schönlein, Martin, Ammatuna, Emanuele, Meers, Stef, Delia, Mario, Stojanoski, Zlate, Nordlander, Anna, Lahmer, Tobias, Pinczés, László Imre, Buquicchio, Caterina, Piukovics, Klára, Ormazabal-Vélez, Irati, Fracchiolla, Nicola S., Samarkos, Michail, Méndez, Gustavo-Adolfo, Hernández-Rivas, José Ángel, Espigado, Ildefonso, Čerňan, Martin, Petzer, Verena, Lamure, Sylvain, Blasi, Roberta di, Marques de Almedia, Joyce, Dargenio, Michelina, Biernat, Monika, Sciumè, Mariarita, Ramón, Cristina de, Jonge, Nick de, Batinić, Josip, Aujayeb, Avinash, Marchetti, Monia, Fouquet, Guillemette, Fernández, Noemí, Zambrotta, Giovanni, Sacchi, Maria Vittoria, Guidetti, Anna, Demirkan, Fatih, Prezioso, Lucia, Ráčil, Zdeněk, Nucci, Marcio, Mladenovic, Milos, Lievin, Raphaël, Hanakova, Michaela, Gräfe, Stefanie, Sili, Uluhan, Machado, Marina, Cattaneo, Chiara, Adžić-Vukičević, Tatjana, Verga, Luisa, Labrador, Jorge, Rahimli, Laman, Bonanni, Matteo, Passamonti, Francesco, Pagliuca, Antonio, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Busca, Alessandro, and Cornely, Oliver A.
Abstract: Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received ≤2 vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P < .001), active HM (P < .001), and severe and critical COVID-19 (P = .007 and P < .001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P < .001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P < .001) or combined with antivirals (P = .009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.
Published: 2022

50. Simultaneous Onset of Haematological Malignancy and COVID:An Epicovideha Survey

Author: Cattaneo, Chiara, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Itri, Federico, Weinbergerová, Barbora, Gomes Da Silva, Maria, Dargenio, Michelina, Dávila-Valls, Julio, Martín-Pérez, Sonia, Farina, Francesca, Van Doesum, Jaap, Valković, Toni, Besson, Caroline, Poulsen, Christian Bjørn, López-García, Alberto, Žák, Pavel, Schönlein, Martin, Piukovics, Klára, Jaksic, Ozren, Cabirta, Alba, Ali, Natasha, Sili, Uluhan, Fracchiolla, Nicola, Dragonetti, Giulia, Adžić-Vukičević, Tatjana, Marchetti, Monia, Machado, Marina, Glenthøj, Andreas, Finizio, Olimpia, Demirkan, Fatih, Blennow, Ola, Tisi, Maria Chiara, Omrani, Ali S., Navrátil, Milan, Ráčil, Zdeněk, Novák, Jan, Magliano, Gabriele, Jiménez, Moraima, Garcia-Vidal, Carolina, Erben, Nurettin, Del Principe, Maria Ilaria, Buquicchio, Caterina, Bergantim, Rui, Batinić, Josip, Al-Khabori, Murtadha, Verga, Luisa, Szotkowski, Tomáš, Samarkos, Michail, Ormazabal-Vélez, Irati, Meers, Stef, Maertens, Johan, Pinczés, László Imre, Hoenigl, Martin, Drgoňa, Ľuboš, Cuccaro, Annarosa, Bilgin, Yavuz M., Aujayeb, Avinash, Rahimli, Laman, Gräfe, Stefanie, Sciumè, Mariarita, Mladenović, Miloš, Çolak, Gökçe Melis, Sacchi, Maria Vittoria, Nordlander, Anna, Berg Venemyr, Caroline, Hanáková, Michaela, García-Poutón, Nicole, Emarah, Ziad, Zambrotta, Giovanni Paolo Maria, Nunes Rodrigues, Raquel, Cordoba, Raul, Méndez, Gustavo Adolfo, Biernat, Monika M., Cornely, Oliver A., Pagano, Livio, Cattaneo, Chiara, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Itri, Federico, Weinbergerová, Barbora, Gomes Da Silva, Maria, Dargenio, Michelina, Dávila-Valls, Julio, Martín-Pérez, Sonia, Farina, Francesca, Van Doesum, Jaap, Valković, Toni, Besson, Caroline, Poulsen, Christian Bjørn, López-García, Alberto, Žák, Pavel, Schönlein, Martin, Piukovics, Klára, Jaksic, Ozren, Cabirta, Alba, Ali, Natasha, Sili, Uluhan, Fracchiolla, Nicola, Dragonetti, Giulia, Adžić-Vukičević, Tatjana, Marchetti, Monia, Machado, Marina, Glenthøj, Andreas, Finizio, Olimpia, Demirkan, Fatih, Blennow, Ola, Tisi, Maria Chiara, Omrani, Ali S., Navrátil, Milan, Ráčil, Zdeněk, Novák, Jan, Magliano, Gabriele, Jiménez, Moraima, Garcia-Vidal, Carolina, Erben, Nurettin, Del Principe, Maria Ilaria, Buquicchio, Caterina, Bergantim, Rui, Batinić, Josip, Al-Khabori, Murtadha, Verga, Luisa, Szotkowski, Tomáš, Samarkos, Michail, Ormazabal-Vélez, Irati, Meers, Stef, Maertens, Johan, Pinczés, László Imre, Hoenigl, Martin, Drgoňa, Ľuboš, Cuccaro, Annarosa, Bilgin, Yavuz M., Aujayeb, Avinash, Rahimli, Laman, Gräfe, Stefanie, Sciumè, Mariarita, Mladenović, Miloš, Çolak, Gökçe Melis, Sacchi, Maria Vittoria, Nordlander, Anna, Berg Venemyr, Caroline, Hanáková, Michaela, García-Poutón, Nicole, Emarah, Ziad, Zambrotta, Giovanni Paolo Maria, Nunes Rodrigues, Raquel, Cordoba, Raul, Méndez, Gustavo Adolfo, Biernat, Monika M., Cornely, Oliver A., and Pagano, Livio
Abstract: Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.
Published: 2022

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

161 results on '"Nordlander, Anna"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources